Y017005 1 
81007110
COMPUTER CONTROL OF AN IMED-929 INFUSION PUMP
KENNY G N C; RENNIE R; TOAL F; RIED J A
UNIV. DEPARTMENT OF ANESTHESIA, ROYAL INFIRMARY, 8-16 ALEXANDRA PARADE, GLASGOW G31 2ER, UK.
J MED ENG TECHNOL 9 (5). 1985. 227-228. CODEN: JMTED
Lang.: Eng.
There is a growing interest in the potential benefits to be obtained from closed-loop control of drug infusion. The most widely available infusion pump which is specifically designed for control by computer is the 929 volumetric infusion pump produced by Imed. The increasing availability of microcomputers suggests that they will be used more frequently to control such pumps. However, difficulties can arise when the attempt is made to establish communication between the computer and the pump and a method employed for this purpose is described in this article. The aim was to provide a simple method of conducting the required communication between the computer and the pump using a high-level language. The commands specified in the high-level language are passed to a machine-code subroutine which organizes transmission to and receives data from the pump.
Desc.: DRUG-DELIVERY SYSTEM COMPUTERS BIOMEDICAL INSTRUMENTATION
Concept Codes: GENL BIOL-INFRMTN, DOCU, COMP APPL (*00530); MATHEMATIC BIOL/STATISTIC METH (04500); BIOCHEM STUD-GENERAL (10060); BIOPHYS-BIOENGINEERING (*10511); PATHOLOGY-THERAPY (12512); CARDIOVASC SYST-GENL STUDS, METHS (14501); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-CLINICAL PHARMACOL (*22005); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)

Y017005 2 
81006823
BLOOD PRESSURE REGULATION BY COMPUTER-CONTROLLED INFUSION OF VASODILATORS
HOENIG R; SCHULZ V; LOESCHCKE G
MED. KLIN. I UNIV. KOELN, JOSEPH-STELZMANN-STRASSE 9, D-5000 KOELN 41.
BIOMED TECH 30 (6). 1985. 134-138. CODEN: BMZTA
Lang.: GERMAN
A computer controlled infusion of short-acting vasodilating drugs for rapid and reliable reduction of increased blood-pressure is described in the following article. In comparison with conventional management the automatic device achieves greater stability of blood-pressure regulation and saves work for the staff.
Desc.: HUMAN NITROPRUSSIDE ANTIHYPERTENSIVE-DRUG DRUG-DELIVERY SYSTEM BIOMEDICAL INSTRUMENTATION
Concept Codes: GENL BIOL-INFRMTN, DOCU, COMP APPL (*00530); MATHEMATIC BIOL/STATISTIC METH (04500); BIOCHEM STUD-GENERAL (10060); BIOPHYS-BIOENGINEERING (*10511); PATHOLOGY-THERAPY (12512); CARDIOVASC SYST-GENL STUDS, METHS (14501); CARDIOVASC SYST-BLD VESS PATHOL (*14508); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-CARDIOVASC SYST (*22010); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100); PUB HEALTH-HEALTH SERV, MEDL CARE (*37012)  Biosystematic Codes: HOMINIDAE (86215)

Y017005 3
>>>Accession number 1949490 is unavailable

Y017005 4
>>>Accession number 1949158 is unavailable

Y017005 5
>>>Accession number 1949154 is unavailable

Y017005 6
>>>Accession number 1949140 is unavailable

Y017005 7
>>>Accession number 1948871 is unavailable

Y017005 8 
30035258 
PULSATILE LHRH THERAPY OF HYPOGONADOTROPIC HYPOGONADISM
NILLIUS S J
SECT. REPRODUCTIVE ENDOCRINOL. INFERTILITY, DEP. OBSTET. GYNECOL., UNIV. HOSP., S-751 85 UPPSALA, SWED.
VENTUROLI, S., C. FLAMIGNI AND J. R. GIVENS. ADOLESCENCE IN FEMALES: 8TH ANNUAL SYMPOSIUM ON GYNECOLOGIC ENDOCRINOLOGY, BOLOGNA, ITALY, OCT. 24-26, 1983. XXVII+508P. YEAR BOOK MEDICAL PUBLISHERS, INC.: CHICAGO, ILL., USA. ILLUS. ISBN 0-8151-3532-7. 0 (0). 1985. 287-308. CODEN: 21643
Lang.: Eng.
Desc.: HUMAN HORMONE-DRUG PUBERTY INITIATION AUTOMATIC INFUSION PUMP
Concept Codes: GENL BIOL-SYMPOSIA, PROCDNGS, REVW (00520); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-BIOENGINEERING (10511); PATHOLOGY-THERAPY (*12512); METABOLISM-METABOLIC DISORDERS (*13020); REPRODUCT SYST-GENL STUDS, METHS (16501); REPRODUCT SYST-PATHOLOGY (*16506); ENDOCRINE SYST-GONADS, PLACENTA (*17006); ENDOCRINE SYST-NEUROENDOCRINOLOG (*17020); NERVOUS SYST-PHYSIOL, BIOCHEM (20504); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); PHARMACOL-NEUROPHARMA COLOGY (22024); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100); PEDIATRICS (*25000); DEVELOPMNTL BIOL-GEN MORPHGENSIS (*25508)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 9 
30016638
DEVELOPMENT OF ANTITHROMBOGENIC ELASTOMERS WITH CONTROLLED RELEASE OF ANTICOAGULANT
MATSUDA T; IWATA H; TOYOSAKI T; NODA H; NAKATANI T; FUKUDA Y; ADACHI S; TAKANO T; AKUTSU T
22ND ANNUAL MEETING OF THE JAPANESE SOCIETY FOR ARTIFICIAL ORGANS AND TISSUES, OSAKA, JAPAN, NOV. 9-10, 1984. ARTIF ORGANS 9 (3). 1985. 308.
CODEN: ARORD
Lang.: Eng.
Desc.: ABSTRACT MD-805 HYDROPHILIC POLYETHYLENE OXIDE-BASED SEGMENTED POLYURETHANES RELEASE RATE RELEASE DURATION DRUG DELIVERY SYSTEM
Concept Codes: GENL BIOL-SYMPOSIA, PROCDNGS, REVW (00520); BIOPHYS-BIOENGINEERING (*10511); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-BLOOD, HEMATO AGENTS (*22008)

Y017005 10 
30013061
GLUCOSE MONITORING AND INSULIN ADMINISTRATION IN THE PREGNANT DIABETIC PATIENT
LANDON M B; GABBE S G
HOSP. UNIV. PENNSYLVANIA, DEP. OBSTETRICS AND GYNECOL., 3400 SPRUCE ST., PHILADELPHIA, PA 19104.
CLIN OBSTET GYNECOL 28 (3). 1985. 496-506. CODEN: COGYA
Lang.: ENG.
Desc.: HUMAN ANTIDIABETIC-DRUG HORMONE-DRUG PORTABLE DOSAGE COMPUTER INFUSION PUMP
Concept Codes: GENL BIOL-INFRMTN, DOCU, COMP APPL (*00530); CLIN BIOCHEM-GENL STUDIES (*10006); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-CARBOHYDR. (10068); BIOPHYS-BIOENGINEERING (*10511) PATHOLOGY-THERAPY (*12512); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-PROTNS, PEPTDS, AM ACDS (13012); METABOLISM-METABOLIC DISORDERS (*13020); REPRODUCT SYST-PATHOLOGY (*16506); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-DRUG METAB, METAB STIM (22003); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); PHARMACOL-REPRODUCT SYST, IMPLANT (?2-?028); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 11 
30005197
CONTROLLED RELEASE OF DRUG MODEL FROM N-2 HYDROXYPROPYL-METHACRYLAMIDE COPOLYMERS
KOPECEK J; REJMANOVA P; DUNCAN R; LLOYD J B
INST. MACROMOLECULAR CHEM., CZECH. ACAD. SCI., 162 06 PRAGUE 6, CZECH.
TIRRELL, D. A., L. G. DONORUMA AND A. B. TUREK (ED.). ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, VOL. 446. MACROMOLECULES AS DRUGS AND AS CARRIERS FOR BIOLOGICALLY ACTIVE MATERIALS; MEETING, NEW YORK, N.Y., USA, MAR. 26-28, 1984. IX+458P. NEW YORK ACADEMY OF SCIENCES: NEW YORK, N.Y., USA. ILLUS. ISBN 0-89766-287-3 (PAPER); ISBN 0-89766-286-5 (CLOTH). 0 (0). 1985. 3-104. CODEN: ANYAA
Lang.: Eng.
Desc.: DRUG DELIVERY
Concept Codes: GENL BIOL-SYMPOSIA, PROCDNGS, REVW (00520); BIOCHEM STUD-GENERAL (*10060); BIOPHYS-MOLECUL PROP, MACROMOLEC (10506); PHARMACOL-GENERAL STUDIES (*22002)

Y017005 12 
30005194
CONTROLLED DRUG RELEASE FROM POLYORTHO ESTERS
HELLER J
POLYMER SCI. DEP., SRI INT., MENLO PARK, CA 94025.
TIRRELL, D. A., L. G. DONARUMA AND A. B. TUREK (ED.). ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, VOL. 446. MACROMOLECULES AS DRUGS AND AS CARRIERS FOR BIOLOGICALLY ACTIVE MATERIALS; MEETING, NEW YORK, N.Y., USA, MAR. 26-28, 1984. IX+458P. NEW YORK ACADEMY OF SCIENCES: NEW YORK, N.Y., USA. ILLUS.
ISSN 0-89766-287-3 (PAPER); ISBN 0-89766-286-5 (CLOTH). 0 (0). 1985. 51-66. CODEN: ANYAA
Lang.: Eng.
Desc.: CALCIUM LACTATE ANHYDRIDES DRUG DELIVERY
Concept Codes: GENL BIOL-SYMPOSIA, PROCDNGS, REVW (00520); BIOCHEM STUD-GENERAL (*10060); BIOPHYS-MOLECUL PROP, MACROMOLEC (*10506); PHARMACOL-GENERAL STUDIES (*22002)

Y017005 13 
30005190
CONTROLLED RELEASE AND MAGNETICALLY MODULATED SYSTEMS FOR MACROMOLECULAR DRUGS
LANGER R; SIEGEL R; BROWN L; LEONG K; KOST J; EDELMAN E
DEP. APPLIED BIOLOGICAL SCI., MASS. INST. TECHNOLOGY, CAMBRIDGE, MA 02139.
TIRRELL, D. A., L. G. DONARUMA AND A. B. TUREK (ED.). ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, VOL. 446. MACROMOLECULES AS DRUGS AND AS CARRIERS FOR BIOLOGICALLY ACTIVE MATERIALS; MEETING, NEW YORK, N.Y., USA, MAR. 26-28, 1984. IX+458P. NEW YORK ACADEMY OF SCIENCES: NEW YORK, N.Y., USA. ILLUS. ISBN 0-89766-287-3 (PAPER); ISBN 0-89766-286-5 (CLOTH). 0 (0). 1985. 1-13. CODEN: ANYAA
Lang.: Eng.
Desc.: DRUG DELIVERY SYSTEM
Concept Codes: GENL BIOL-SYMPOSIA, PROCDNGS, REVW (00520); BIOCHEM STUD-GENERAL (10060); PHARMACOL-GENERAL STUDIES (*22002)

Y017005 14 
3000061
ORAL CONTROLLED-RELEASE DELIVERY OF IVERMECTIN IN CATTLE VIA AN OSMOTIC PUMP
POPE D G; WILKINSON P K; EGELTON J R; CONROY J
MERCK SHARP, DOHME RES. LAB., RAHWAY, N.J. 07065.
J PHARM SCI 74 (10). 1985. 1108-1110. CODEN: JPMSA
Lang.: Eng.
Desc.: ANTIPARASITIC-DRUG DRUG DELIVERY PHARMACOKINETICS PHARMACEUTICAL INDUSTRY CATTLE INDUSTRY
Concept Codes: BIOCHEM STUD-CARBOHYDR. (10068); METABOLISM-CARBOHYDRATES (13004); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003); VETERINARY SCI-GENL STUDS, METHS (*380?2); CHEMOTHERAPY-ANTIPARASITIC AGNTS (*38510); PEST CONTRL GENL/PESTICS/HERBICS (*54600); ECONOM ENTOMOL-ANIMAL PESTS (*60012); ECONOM ENTOMOL-CHEM PHYS CONTRL (*60016); PARASITOLOGY-VETERINARY (*60506)
Biosystematic Codes: BOVIDAE (85715)

Y017005 15 
80109722
EFFECT OF REPEATED INTRAPERITONEAL INJECTIONS OF SOMAN ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT
HYMOWITZ N; BREZENOFF H E; MCGEE J; CAMPBELL K; KNIGHT V
DEP. PHARMACOLOGY, UNIV. MED. DENTISTRY NEW JERSEY, 100 BERGEN ST., NEWARK, NJ 07103, USA.
PSYCHOPHARMACOLOGY 86 (4). 1985. 404-408. CODEN: PSCHD
Lang.: Eng.
Intraperitoneal (i.p.) administration of the acetylcholinestarase inhibitor, soman (10-40 .mu.g/kg), suppressed in a dose-related manner response rates in rats maintained under a multiple fixed-interval 50-s fixed-ratio 25 schedule of food delivery. Chronic administration of soman at weekly intervals resulted in tolerance to the response. When soman administration was separated by 2-5 wk in individual rats, the suppressive effects of the agent again became apparent. Analysis of acetylcholinisterase activity revealed that enzyme inhibition was limited to gastrointestinal areas near the site of injection. There was no significant effect on brain acetylcholinesterase even following i.p. injection of doses which completely suppressed responding. The i.p.route may be useful for studying tolerance and other chronic effects of soman without producing generalized toxicity.
Desc.: ENZYME INHIBITOR-DRUG ACETYLCHOLINESTERASE INHIBITOR GASTROINTESTINAL AREAS FOOD DELIVERY TOXICITY
Concept Codes: BEHAVIOR BIOL-ANIMAL BEHAVIOR (*070?3); BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); ENZYMES-PHYSIOLOGICAL STUDIES (*?0808); CHORDATE BODY REGNS-ABDOMEN (11314); DIGESTIVE SYST-PATHOLOGY (*14006); NERVOUS SYST-PATHOLOGY (*20506) PSYCHIATRY-PSYCHOPHYSIOLOGY (21003); ROUTES OF IMMUNIZ, INFECT, THERAP (22100) TOXICOL-GENL/EXP STUDS, METHS (*22501); PEST CONTRL GENL/PESTICS/HERBICS (54600); ECONOM ENTOMOL-CHEM PHYS CONTRL (60016)
Biosystematic Codes: MURIDAE (86375)

Y017005 16 
80109396
ACTIVE AND PASSIVE SMOOTH EYE MOVEMENTS EFFECTS OF STIMULUS SIZE AND LOCATION
POLA J; WYATT H J
STATE UNIV. N.Y., STATE COLL. OPTOMETRY, 100 EAST 24TH ST., NEW YORK, N.Y. 10010, USA.
VISION RES 25 (8). 1985. 1063-1076. CODEN: VISRA
Lang.: Eng.
We measured active smooth pursuit eye movements and passive smooth eye movements in the open-loop condition as subjects viewed among stimuli of different sizes and at various retinal loci. Active movements have high gain and relatively large phase lag. Passive movements have lower gain and smaller phase lag, and occur with either foveal or eccentric stimuli. They appear to be similar or identical of optokinetic movements. Although different, active and passive movements show a similar increase in amplitude and phase lag as the size of the stimulus was increased. From these findings we suggest that: (1) the stimuli for the active movements are target position and velocity; (2) the stimulus for passive movements is target velocity; and (3) the active response to target velocity is related, in part, to the passive response and thus is related to optikinesis.
Desc.: HUMAN OPTOKINESIS VELOCITY POSITION
Concept Codes: MOVEMENT (12100); MUSCLE SYST-GENLSTUDS, METHS (*17501); MUSCLE SYST-PHYSIOL, BIOCHEM (*17504); SENSE ORGANS-GENL STUDS, METHS (*20001) SENSE ORGANS-PHYSIOL, BIOCHEM (*20004)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 17 
80109353
PERCEPTUAL DELAY OF THE AMENDMENT SIGNAL IN DUAL-RESPONSE SITUATIONS AS A FUNCTION OF MOVEMENT SPEED
WILLIAMS L R T; SULLIVAN S J; DOUGLAS J R
FACULTY OF PHYSICAL EDUCATION, UNIV. OF OTAGO, P. O. BOX 56, DUNEDIN, NEW ZEALAND.
J HUM MOV STUD 11 (3). 1985. 145-150. CODEN: JHMSD
Lang.: Eng.
Conscious perception of the time of occurrence of the 2nd of a pair of closely spaced stimuli was examined for an extended arm swing as a function of movement speed. A dual-response paradigm was used. A substantial perceptual delay was found whether or not the amendment (reversal) of the primary swing was required. Under conditions where the 1st reaction period was not required, the delay has almost completely removed-thereby supporting sequential processing views. For the speed conditions (maximal, 2/3 and 1/3) the perceptual delay increased with movement speed and was in accordance with the idea that open loop control can have a biassing effect on the conscious awareness of serial events.
Desc.: HUMAN SEQUENTIAL PROCESSING CONSCIOUS AWARENESS OF SERIAL EVENTS
Concept Codes: BEHAVIOR BIOL-HUMAN BEHAVIOR (07004); MOVEMENT (*12100);  SENSE ORGANS-PHYSIOL, BIOCHEM (*20004); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504) PSYCHIATRY-PSYCHOPHYSIOLOGY (*21003)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 18 
80107315
ASSESSMENT OF GELLING IN INSULIN SOLUTIONS FOR INFUSION PUMPS
HUTCHISON K G
WYETH RES. LTD, HUNTERCOMBE LANE SOUTH, TAPLOW, MAIDENHEAD, BERKS, SL6 0PH, UK.
J PHARM PHARMACOL 37 (8). 1985. 528-531. CODEN: JPPMA
Lang.: Eng.
Prolonged, gentle agitation of ?100 insulin solutions containing various ingredients has shown that gelling can take place. The extent of gelling was evaluated by low shear rheometry and quantified in terms of the effective MW increase using the method of reduced variables. Maximal viscosities of gelled systems in excess of 100 Pas were achieved. From a knowledge of the hydrodynamics of infusion pump systems, the reduction in insulin delivery rate caused by an increase in viscosity can be calculated. In commercial, syringe-driven pumps, pressure differentials as high as 104/Nm and shear rates in excess of 104/s can occur, although the flow is invariably laminar.
Desc.: ANTIDIABETIC-DRUG HORMONE-DRUG
Concept Codes: COMPARATIVE BIOCHEM-GENL STUDIES (*10010); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); PATHOLOGY-THERAPY (*12512); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-METABOLIC DISORDERS (*13020); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-CLINICAL PHARMACOL (22005); PHARMACOL-ENDOCRINE SYST (*22016); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)

Y017005 19 
80107012
HEPARIN ELIMINATION FOLLOWING CONTINUOUS INFUSION DURING INTRA-AORTIC BALLOON COUNTERPULSATION
JACOB A S; STEINGART R H; SCHWEGER M J
DIV. CARDIOLOGY, MARICOPA MED. CENTER, P.O. BOX 5099, PHOENIX, AZ 85010.
CATHETERIZATION CARDIOVASC DIAGN 11 (4). 1985. 389-392. CODEN: CCDID
Lang.: Eng. 
The decline of the activated partial thromboplastin time (APTT) following discontinuation of heparin infusion was measured in 6 intra-aortic ballon pump (IABP) patients. The heparin infusion requirement was determained for 8 other IABP patients during stable therapeutic anticoagulation. Following discontinuation of infusion, APTT declined with a relatively constant half-life (t1/2 of 2.4 .+-. 0.08 h), suggesting elimination by 1st-order kinetics. In comparison, the t1/2 following single bolus doses has been shown to be markedly dose dependent, increasing from 30 min at low doses to 2 h at very high doses. The heparin requirement for IABP patients was 16 .+-. 2.5 U/kg per h, similar to that reported for other clinical situations. The t1/2 of the APTT following discontinuation of heparin infusion can be used to time invasive procedures that would best be done with normal hemostasis.
Desc.: HUMAN ANTICOAGULANT-DRUG ACTIVATED PARTIAL THROMBOPLASTIN TIME HEMOSTASIS PHARMACOKINETICS
Concept Code: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-BIOENGINEERING (10511); ENZYMES-GEN, COMPAR STUD, ?OENZYMS (10802); ANATOMY/HISTOL-SURGERY (*11105); PATHOLOGY-THERAPY (12512); CARDIOVASC SYST-GENL STUDS, METHS (*14501); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (*15002); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-BLOOD, HEMATO AGENTS (*22008); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 20 
80102042
THE VECTORCARDIOGRAM IN MUCOCUTANEOUS LYMPH NODE SYNDROME PATIENTS WIDE
T-LOOP AND OPEN QRS-LOOP
SUZUKI T; SONE K; ONO S
DEP. PEDIATRICS, GUNMA CHILDREN'S MED. CENT.
KITAKANTO MED J 35 (2). 1985. 185-189. CODEN: KKAIA
Lang.: JAPANESE
Vectorcardiograms were recorded from 159 patients with MCLS [Mucocutaneous lymph node syndrome] and 75 normal children. The ages of MCLS cases ranged from 6 months to 15 years, while those of the normal children ranged from 7 months to 13 years. The maximal length to width ratios of spacial T loop (L/W), open QRS-loop and its ST vector were studied. The criteria of wide-T loop was defined as less than 3.4, which is the 5th percentile lower limit for normal children. Among the MCLS patients, there were 26 cases (26/159, 16.4%) with wide T-loop: 8 of these were in a coronary dilatation group (8/30, 26.7%) While the remaining 18 cases were in a cororary noremal group (18/107, 16, 8%). By contrast, there were no wide T-loop cases in a coronary aneurysm group. With regard to the ratio of open QRS and the value of ST vector, there was no significant difference between normal children and those with MCLS, but in the coronary aneurysms group many open QRS-loop and large ST vector cases were seen. Because wide T-loop is one of the signs of myocardial damage, the results show that some myocardial damage persists in MCLS patients. This myocardial damage seems to be port myocardial changes due to myocarditis in MCLS.
Desc.: MUCOCUTANEOUS LYMPH NODE SYNDROME CORONARY DILATATION MYOCARDITIS
Concept Codes: EXTERN EFF-ELECTR, MAGNET, GRAVITY (10610); PATHOLOGY-DIAGNOSTIC (*12504); PATHOLOGY-INFLAMMATN, INFLAM DIS (*12508); CARDIOVASC SYST-GENL STUDS, METHS (14501); CARDIOVASC SYST-HEART PATHOLOGY (*14546); BLOOD/BODY FLDS-BLD, LYM, RES PATH (*15006); BLOOD/BODY FLDS-LYMPHAT TISS, RES (*15008); INTEGUMENT SYST-PATHOLOGY (*18506)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 21 
80100553
BIOCHEMICAL AND BEHAVIORAL CHANGES IN RTS DURING AND AFTER CHRONIC D AMPHETAMINE EXPOSURE
VOGEL W H; MILLER J; WAXMAN H; GOTTHEIL E
DEP. PHARMACOL., THOMAS JEFFERSON UNIV., PHILDELPHIA, PA 19107, USA.
DRUG ALCOHOL DEPEND 15 (3). 1985. 245-254. CODEN: DADED
Lang.: Eng.
Two groups of rats were implanted with ALZET minipumps to deliver vehicle or a theoretical amount of 1 mg/kg per h of diamphetamine (A) for 12 days. After 3 days of A-exposure, motor movements and stereotypic behavior were markedly increased. Subsequent testing during A-exposure showed that motor movements and stereotypic behavior remained significantly increased but declined. After removal of the pumps, these effects disappeared and no differences at rest, during stress or A challenge, were apparent in either group. Animals sacrificed after 3 days of drug exposure, showed a drastic decrease in cardiac, but not adrenal, catecholamine levels. In the brain, norepinephrine (NE) levels were markedly decreased in the frontal cortex, hypothalamus, caudate, pons-medulla and cerebellum. Epinephrine (E) levels were unaffected and dopamine (DA) levels were decreased in most areas without reaching statistical significance. Plasma corticosterone levels were similar in both groups. Animals in both groups sacrificed about 25 days afetr pump removal were biochemically similar. Under the present conditions, A-exposure produced marked behavioral and biochemical changes but there was no evidence of residual abnormalities after cessation of drug treatment.
Desc.: PHARMACOTOXICITY CATECHOLAMINE
Concept Codes: BEHAVIOR BIOL-ANIMAL BEHAVIOR (*07003); CLIN BIOCHEM-GENL STUDIES (10006); BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-STEROLS, STEROIDS (10067); PHYSIOLOGY-STRESS (*12008); METABOLISM-STEROLS, STEROIDS (*13008); METABOLISM-PROTNS, PEPTDS, AM ACDS (*1?012); CARDIOVASC SYST-PHYSIOL, BIOCHEM (*14504); CARDIOVASC SYST-HEART PATHOLOGY (*14506); BLOOD/BODY FLDS BLOOD, LYMPH STUD (15002); ENDOCRINE SYST-ADRENALS (*17004); ENDOCRINE SYST-NEUROENDOCRINOLOG (*17020); MUSCLE SYST-PHSYIOL, BIOCHEM (*17504); MUSCLE SYST-PATHOLOGY (*17506); NERVOUS SYST-GENL STUDS, METHS (20501); NERVOUS SYST-ANATOMY (*20502); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504); NERVOUS SYST-PATHOLOGY (*20506); PSYCHIATRY-PSYCHOPHYSIOLOGY (*21003); PSYCHIATRY-ADDICTION (INC SMOKNG) (*21004); PHARMACOL-NEUROPHARMACOLOGY (*22024); PHARMACOL-PSYCHOPHARMACOLOGY (*22026); TOXICOL-PHARMACOLOGICAL (*22504)
Biosystematic Codes: MURIDAE (86375)

Y017005 22 
80100004
DYNAMIC CONTROL OF THE PERIORAL SYSTEM DURING SPEECH KINEMATIC ANALYSES OF AUTOGENIC AND NONAUTOGENIC SENSORIMOTOR PROCESSES
GRACCO V L; ABBS J H
SPEECH MOTOR CONTROL LAB., WAISMAN CENT., UNIV. WIS., MADISON, WIS. 53705-2280.
J NEUROPHYSIOL (BETHESDA) 54 (2). 1985. 418-432. CODEN: JONEA
Lang.: Eng.
Afferent contributions to the motor control of speech were evaluated by applying unanticipated loads to the lower lip during the combined upper lip-lower lip gesture associated with the oral closing movements for a b sound. Loads were introduced randomly in .apprx. 15% of the trials to minimize subject anticipation or adaptation. A total of 490 load trials (in 5 naive subjects) were distributed within a restricted interval (100 ms) centered on the initiation of agonist muscle contraction associated with the lip-closing movements. Kinematic adjustments of the upper and lower lips to these perturbations were examined in detail. In all subjects, load-induced changes in upper and lower lip displacement, movement time, and closing velocity were statistically significant and observed the 1st time a perturbation was introduced. Load timing variations within the target interval resulted in systematic changes in the site of the compensatory adjustments (upper versus lower lip) and in the magnitude of the kinematic responses. These kinematic changes appeared to reflect the dynamic nature of underlying control processes and clearly contrasted the different response characteristics of autogenic (lower lip) and nonautogenic (upper lip) compensatory actions. Although both upper and lower lip adjustments contributed to perturbation compensations, autogenic responses predominated when loads occurred 20-55 ms before muscle activation. For these early loads, autogenic responses provided .apprx. 75% of the total compensation. For later loads, when the evolving speech motor action was more time constrained, nonaurogenic (open-loop) compensations predominated, providing .apprx. 65% of the total compensation. The variations in upper and lower lip compensatory response magnitude did not parallel the time course of facial muscle activation. Lower lip kinematic adjustments were reduced 10-15 ms prior to the onset of agonist muscle activation, whereas upper lip adjustments increased in magnitude 10-20 ms after agonist onset. The dynamic modulation of these responses is controlled independently from facial motoneuron excitation, possibly involving sensorimotor processing via supranuclear centers. The compensatory movement dsiplacements were highly related to the magnitude of the perturbation displacement, especially for loads introduced prior to agonist muscle onset, reflecting a well-calibrated readjustment. Responses to later loads were less consistently related to perturbation didplacement. Although compensatory displacements were manifest in a calibrated manner, adjustments in movement velocity and movement time were more variable and appeared to be subordinate to displacement adjustments. In 1 of the subjects movement velocity and mov ement time was strikingly different from those of the other subjects. Even in a motor task such as speech, where some temporal constraints are manifest, the nervous system control process has flexibility in disassociating these kinematic variables. Afferent information from the perioral region is used in multiple ways in control of lip movements for speech. Prior to agonist muscle activation, based on the well-calibrated responses afferent information is seemingly used to specify and update control parameters as part of what was termed motor programming. Once motor execution is under way, afferent input is used to shape the evolving motor output, primarily via nonautogenic adjustments, to ensure achievement of multimovement goals.
Desc.: HUMAN MOTOR PROGRAMMING FACIAL MUSCLE LIP MOVEMENT
Concept Codes: BIOPHYS-BIOCYBERNETICS (10515); MOVEMENT (12100); MUSCLE SYST-GENL STUDS, METHS (17501); MUSCLE SYST-PHYSIOL, BIOCHEM (*17504); DENTAL/ORAL BIOL-GENL STUD, METHS (19001); DENTAL/ORAL BIOL-PHYSIOL, BIOCHEM (*19004); SENSE ORGANS-GENL STUDS, METHS (20001); SENSE ORGANS-DEAFNSS, SPEECH-, HEAR (*20008);  NERVOUS SYST-GENL STUDS, METHS (20501); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 23 
80098606
INFLUENCE OF FOOD ON THE RATE AND EXTENT OF ABSORPTION OF THEOPHYLLINE AFTER SINGLE DOSE ORAL ADMINISTRATION OF A CONTROLLED RELEASE TABLET
LAGAS M; JONKMAN J H G
LAB. PHARMACEUTICAL RESEARCH, HAVEZATHENLAAN 2, 9301 SL RODEN, THE NETHERLANDS.
INT J CLIN PHARMACOL THER TOXICOL 23 (8). 1985. 424-426. CODEN: IJCPB
Lang.: Eng.
Rate and extent of absorption of theophylline were determined in 7 healthy volunteers on pre- as well as on postprandial administration of commercially available controlled release tablets (Theograd -350 mg). In fasting subjects, maximum serum theophylline concentrations of 3.8 .+-. 1.2 mg .cntdot. l-1 (mean .+-. SD) were reached at 3.4 .+-. 1.2 h after dosing; under nonfasting conditions maximum serum levels of 5.8 .+-. 1.3 mg .cntdot. l-1 were found at 7.4 .+-. 1.4 h after the tablet was given. The bioavailability increased from 65 .+-. 8%, observed on preprandial administration to 87 .+-. 14%, when Theograd -350 mg tablets were taken after a meal. Theograd -350 mg tablets have a predictable absorption and give relatively high (87%) bioavailability, if the tables are taken after a meal.
Desc.: HUMAN DRUG DELIVERY SYSTEM FOOD-DRUG INTERACTION PHARMACOKINETICS
Concept Codes: CLIN BIOCHEM-GENL STUDIES (10006); BIOCHEM STUD-GENERAL (10060); BIOPHYS-GENERAL BIOPHYS TECH (10504); NUTRITION-GENL, NUTR STATUS, METHS (*13202); RESPIRATORY SYST-GENL STUD, METHS (*16001); DENTAL/ORAL BIOL-GENL STUD, METHS (19001); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-CLINICAL PHARMACOL (*2005); PHARMACOL-RESPIRATORY SYST (*22030)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 24 
80098569
TOTAL UTERINE ACTIVITY IN INDUCED LABOR AN INDEX OF CERVICAL AND PELVIC TISSUE RESISTANCE
ARULKUMARAN S; GIBB D M F; RATNAM S S; LUN K C; HENG S H
KING'S COLLEGE HOSPITAL, DENMARK HILL, LONDON SE5 8RX.
BR J OBSTET GYNAECOL 92 (7). 1985. 693-697. CODEN: BJOGA
Lang.: Eng.
Uterine activity was studied during labor induced using an automatic infusion system (AIS) or a peristaltic infusion pump (IVAC) to administer oxytocin. In the 110 patients who achieved vaginal delivery, the total uterine activity required to effect full dilatation of the uterine cervix was found to vary according to parity and cervical score, but not according to mode of oxytocin infusion. Irrespective of whether the uterine activity level/15 min was maintained at between 700-1500 kPa [kilopascals] or at between 1500-2000 kPa, the total uterine activity was similar the lower levels being compensated for by a longer duration. Fetal outcome, in terms of 1- and 5-min Apgar scores and umbilical vein blood pH, was unaffected by the level of uterine activity. The cervical and pelvic tissue resistance varies according to parity and cervical score. The uterus must achieve a certain total uterine activity in induced labor which is best achieved by maintaining optical uterine activity levels of 1500-2000 kPa/15 min to effect vaginal delivery of the baby in good condition in optimal time.
Desc.: HUMAN OXYTOCIN OXYTOCIC-DRUG PARITY CERVICAL SCORE
Concept Codes: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-GENERAL BIOPHYS TECH (10504); CHORDATE BODY REGNS-PELVIS (11316); BLOOD/BODY FLDS-GENL STUDS, METHS (*15001); REPRODUCT SYST-GENL STUDS, METHS (*16501); REPRODUCT SYST-PHYSIOL, BIOCHEM (*16504); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 25 
80098568
A COMPARATIVE STUDY OF METHODS OF OXYTOCIN ADMINISTRATION FOR INDUCTION OF LABOR
GIBB D M F; ARULKUMARAN S; RATNAM S S
KING'S COLLEGE HOSPITAL, DENMARK HILL, LONDON SE5 8RX.
BR J OBSTET GYNAECOL 92 (7). 1985. 688-692. CODEN: BJOGA
Lang.: Eng.
Equipment has become available for the automatic infusion of oxytocin in a closed loop system for the induction of labor. This system was compared with manual administration of oxytocin by peristaltic infusion pump, the dosage being based on data derived from an intrauterine catheter or by clinical assessment of uterine activity. A Total of 121 patients classified according to parity and cervical score were allocated to an automatic infusion system (AIS) or a peristaltic infusion pump system. Patient characteristics were similar in both groups. Labor was significantly longer in those induced by automatic infusion system particularly in nulliparae and patients with poor cervical scores. In 53.3% of the nulliparae with poor cervical scores the automatic infusion system proved inadequate to effect vaginal delivery. Neonatal outcome was similar in both groups. Automatic infusion of oxotocin by this system increased the length of induced labor and had no statistically significant effect on neonatal outcome, conferring no advantage over a more traditional method of oxytocin administration.
Desc.: HUMAN OXYTOCIC-DRUG AUTOMATIC INFUSION SYSTEM PERISTALTIC INFUSION
Concept Codes: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); EXTERN EFFOPHYSICAL, MECH EFFECTS (10612); REPRODUCT SYST-GENL STUDS, METHS (*16501); REPRODUCT SYST-PHYSIOL, BIOCHEM (*16504); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 26 
80098374
EXTENDED IMMUNOSUPPRESSION WITH CYCLOPHOSPHAMIDE USING CONTROLLED-RELEASE POLYMERIC IMPLANTS
ORMROD D J; CAWLEY S; MILLER T E
DEP. MED., AUCKLAND HOSP., PARK ROAD, AUCKLAND, NEW ZEALAND.
INT J IMMUNOPHARMACOL 7 (4). 1985. 443-448. CODEN: IJIMD
Lang.: Eng.
An effective method of prolonged immunosuppressive therapy using cyclophosphamide incorporated intO acrylic bone cement was developed. The effect of this form of administration of cyclophosphamide on circulating murine immune cells and the inflammatory response was studied. When the slow release mode of cyclophosphamide administration was compared with conventional systemic therapy, it was found to produce a more rapid and prolonged immunosuppression. A dose-response relationship was established and the biological effects of varying the composition and surface area of the implant were determined. The inflammatory response, assessed by measuring the mobilization of cells into s.c. implanted sponges, was also depressed using this mode of administration. These results, coupled with the commercial availability and existing clinical approval of Simplex P bone cement, suggest that the procedure could lead to useful clinical protocols.
Desc.: MOUSE ANTIINFLAMMATORY-DRUG IMMUNOLOGIC-DRUG DRUG DELIVERY SYSTEM SIMPLEX P ACRYLIC BONE CEMENT CIRCULATING IMMUNE CELLS INFLAMMATORY RESPONSE
Concept Codes: CYTOLOGY/CYTOCHEM-ANIMAL (02506); BIOCHEM STUD-GENERAL (10060); BIOPHYS-BIOENGINEERING (*10511); PATHOLOGY-INFLAMMATN, INFLAM DIS (*12508); PATHOLOGY-THERAPY (*12512); BLOOD/BODY FLDS-BLOOD CELL STUDS (*15004); BLOOD/BODY FLDS-LYMPHAT TISS, RES (*15008); BONE, JNTS, FASC, CONN/ADIP-GENL (*18001); INTEGUMENT SYST-GENL STUDS, METHS (18501); PHARMACOL-BLOOD HEMATO AGENTS (22008); PHARMACOL-IMMUNO PROCES, ALLERGY (*22018); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100); IMMUNOL/IMMUNOCHEM-IMMUNOPATHOL (*34508)
Biosystematic Codes: MURIDAE (86375)

Y017005 27 
80098292
PHARMACOKINETICS OF INSULIN INFUSED INTRAPERITONEALLY VIA PORTABLE PUMPS
SELAM J L; RAYMOND M; JACQUEMIN J L; ORSETTI A; RICHARD J L; MIROUZE J
CLINIQUE MALADIES METABOLIQUES ENDOCRINIENNES, HOPITAL LAPEYRONIE, 34059 MONTPELLIER CEDEX.
DIABETE METAB 11 (3). 1985. 170-173. CODEN: DIMED
Lang.: Eng.
Plasma free insulin was measured repeatedly for 4 h following a standardized breakfast in 20 C-peptide negative chronically pumped type I diabetic patients and 5 normal subjects. In the former group, insulin was given as a 1 u/h basal infusion and a 1 h superimposed meal-dose of 6 U via a peritoneal i.p. catheter lying in the low (n = 10), or in the mid-abdomen (n = 10). The results of the i.p. patients were correlated with glycosylated Hb and home capillary blood glucose. Fasting-free insulin of i.p. patients was lower than those of normals (14.7 .+-. 0.5 vs. 21.0 .+-. 1.3 mU/l, P < 0.01). Dose-induced peak occurred similary in i.p. patients and normals (70 .+-. 6 vs. 70 .+-. 12 min). Values tended to baseline after 165 .+-. 15 and 185 .+-. 22 min. in IP patients and normals (not significant). Results of the min, and, low peritoneum subgroups differed only for peak values (31.5 .+-. 2.9 vs. 25.0 .+-. 1.6 mU/l, respectively) and did not correlate with diabete control.
Desc.: HUMAN ANTIDIABETIC-DRUG DRUG DELIVERY SYSTEM
Concept Codes: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-PORPHYRNS, BILE PIGM (10065); BIOCHEM STUD-CARBOHYDR. (10068); CHORDATE BODY RE?NS-ABDOMEN (11314); PATHOLOGY-THERAPY (*12512); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-METABOLIC DISORDERS (*13020); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 28 
80098257
CLOSED-LOOP GLYCEMIC CONTROL IN DIABETICS USING A WEARABLE ARTIFICIAL ENDOCRINE PANCREAS INCORPORATING A NEEDLE-TYPE GLUCOSE SENSOR
HAKUI N
FIRST DEPARTMENT OF MEDICINE, OSAKA UNIV. MEDICAL SCHOOL, OSAKA.
J JPN DIABETES SOC 28 (5). 1985. 613-621. CODEN: TONYA
Lang.: JAPANESE
In the treatment of diabetes mellitus, the normalization of blood glucose on moment-to-moment basis for a long perIod is a desirable goal, since it may prevent or delay the onset of diabetic angiopathies. For this purpose, the wearable artificial endocrine pancreas consisting of a needle-type glucose sensor, a microcomputer system to calCulate insulin and glucagon infusion rates and a 2 roller pump driving system was developed. Firstly the validation and the applicability of a needle-type glucose sensor were investigated in glucose monitoring by inserting it into the subcutaneous tissue of healthy and diabetic volunteers. Secondly, the superiority of closed-loop glycemic control in ambulant diabetic patients using a wearable artificial endocrine pancreas over conventional insulin treatments was examined. The output currents of the needle-type glucose sensor inserted in the subcutaneous tissue of the forearm were significantly correlated with simultaneously monitored blood glucose concentration; it was revealed that the time delay in response was only 4.9 min. The glycemic control obtained by the wearable artificial endocrine pancreas in diabetics was demonstrated to be superior to that by once-a-day intermediate-acting insulin injection regimes, by multiple insulin injections regimes or by continuous subcutaneous insulin infusion regimes. Six day continuous glycemic regulation in a diabetic patient with a wearable artificial endocrine pancreas reveled that there were day-by-day variations of insulin requirements, up to 12 U per day and in the range of from 3-10 U for postprandial glycemic control. When the sensors were kept in the subcutaneous tissue, depressed relative sensor functions with time were recognized. The wearable artificial endocrine pancreas utilizing a needle-type glucose sensor is useful for long-term glycemic control in diabetics, if the sensor is replaced every 4th day. Apparently, to overcome the changes in individual characteristics on minute-by-minute basis, as closed-loop glycemic control system is essential for ambulatory diabetic patients.
Desc.: HUMAN ANTIDIABETIC-DRUG
Concept Codes: GENL BIOL-INFRMTN, DOCU, COMP APPL (00530); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-CARBOHYDR. (10068); BIOPHYS-BIOENGINEERING (*10511); PATHOLOGY-THERAPY (*12512); METABOLISM-CARB-BOHYDRATES (*13004); METABOLISM-METABOLIC DISORDERS (*13020); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); ROUTE OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 29 
80098091
RESULTS OF A RANDOMIZED PROSPECTIVE TRIAL OF INTRAAORTIC BALLOON COUNTERPULSATION AND INTRAVENOUS NITROGLYCERIN IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
FLAHERTY J T; BECKER L C; WEISS J L; BRINKER J A; BULKLEY B H; GERlTEINBLITH G; KALLMAN C H; WEInFELDT M L
JOHNS HOPKINS HOSP., 600 N. WOLFE ST., BALTIMORE, MD. 21205.
J AM COLL CARDIOL 6 (2). 1985. 434-46. CODEN: JACCD
Lang.: Eng.
A randomized prospective clinical trial compared combined treatment with intraaortic balloon pumping and i.v. nitroglycerin for 4 to 5 days with routine clinical management in 20 patients with extensive myocardium at risk for infarction as evidenced by a Tl defect score of 7.0 U or greater. No significant differences in mortality or clinical outcome were observed between the 10 patients receiving the combined treatment and the 10 receiving routine management. In 14 patients 2-dimensional echocardiograms obtained 6-24 h after the onset of symptoms and at follow-up 6-16 days later (after completion of combined intraaortic balloon pumping plus nitroglycerin therapy) were analyzed to determine whether infarct segment or noninfarct segment lengths were affected by therapy. Among these 14 patients, 5 (3 receiving the combined therapy and 2 receiving routne management) demonstrated an increase in infarct segment length of > 1.0 cm. Mean infarct segment length increased 0.30 .+-. 0.44 cm in patients receiving the combined therapy and 0.29 .+-. 0.36 cm in patients on routine management (P = NS [not significant]). Noninfarct segment length increased > 1.0 cm (mean increase 1.20 .+-. 0.39) in 5 of 7 patients on routine management but in none of 7 patients receiving intraaortic balloon pumping plus nitroglycerin therapy (mean decrease 0.22 .+-. 0.20 cm) (P < 0.05). No significant differences were noted in left ventricular ejection fraction, as measured by gated blood pool scintigraphy, or Tl perfusion defect score in a comparison of day 1 (pretreatment) with day 4 Tl or day 7 to 14 gated blood pool scintigrams. Thus, in patients with extensive myocardium at risk, it is unlikely that a reduction in mortality or a significant improvement in myocardial perfusion or ventricular function can be obtained by early intervention with intraaortic balloon pumping in combination with nitroglycerin. Although this combined therapy failed to prevent infarct segment lengthening (infarct expansion), the combined afterload-lowering effects of intraaortic balloon pumping and nitroglycerin did appear to prevent dilation or remodeling of noninfarcted segments during the first 2 wk after acute myocardial infarction.
Desc.: CARDIOVASCULAR-DRUG
Concept Codes: PHOTOGRAPHY-METHS, MATLS, APPARAT (01012); RADIATION BIOL-RADTN ISOTOP TECH (06504); BIOCHEM STUD-GENERAL (10060); MINERALS (10069) ; ANATOMY/HISTOL-SURGERY (11105); ANATOMY/HISTOL-RADIOLOGIC (*11106); PATHOLOGY-NECROSIS (12510); PATHOLOGY-THERAPY (*12512); MINERALS (13010); CARDIOVASC SYST-GENL STUDS, METHS (14501); CARDIOVASC SYST-ANATOMY (*14502); CARDIOVASC SYST-PHYSIOL, BIOCHEM (*14504); CARDIOVASC SYST-HEART PATHOLOGY (*14506); CARDIOVASC SYST-BLD VESS PATHOL (*14508); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-CARDIOVASC SYST (*22010); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 30 
80098065
MECHANISM OF TRANSDERMAL CONTROLLED NITROGLYCERIN ADMINISTRATION 3. CONTROL OF SKIN PERMEATION RATE AND OPTIMIZATION
KESHARY P R; HUANG Y C; CHIEN Y W
CONTROLLED DRUG DELIVERY RESEARCH CENTER, RUTGERS UNIV., COLLEGE OF PHARMACY, BUSCH CAMPUS, P. O. BOX 789, PISCATAWAY, NEW JERSEY 08854.
DRUG DEVIND PHARM 11 (6-7). 1985. 1213-1254. CODEN: DDIPD
Lang.: Eng.
A mathematical model was developed to correlate the drug permeation rate through the skin with the drug release rate from a matrix-type drug delivery system. Experiments were carried out using hairless mouse abdominal skin mounted on a recently-developed and hydrodynamically well-calibrated Keshary-Chien skin permeation system. A matrix-type drug delivery system was designed to contain different loading doses of nitroglycerin and to study the effect of drug loading variation on the rate of drug release, the rate of skin permeation and the equilibrium concentration of nitroglycerin [a vasodilator] in the skin. The stratum corneum evidently plays a significant rate-limiting role in the skin permeation of nitroglycerin across the intact skin, yielding a constant skin permeation profile. The permeation rate across the intact skin was observed to increase with the increase in the drug release flux initially and then levelled off in a hyperbolic fashion. Various constants were obtained from the reciprocal plot of skin permeation rate vs. drug release flu?. These constants could be used for the prediction of the skin permeation rate. A very good correlation between the predicted and the observed values of skin permeation rates was observed. After the stratum corneum was removed by stripping technique, the mechanism and the rate of skin permeation became dominated by the mechanism and the release rate of the delivery system. A linear correlation was observed between the drug permeation rate through the skin and the equilibrium concentration of drug in the skin. This correlation was observed in both intact and viable skins.
Desc.: MOUSE VASODILATOR CARDIOVASCULAR-DRUG STRATUM CORNEUM PHARMACOKINETICS DRUG DELIVERY SYSTEM
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOPHYS-BIOCYBERNETICS (10515) ; METABOLISM-GENL STUD, METAB PATHW (13002); CARDIOVASC SYST-GENL STUDS, METHS (*14501); INTEGUMENT SYST-GENL STUDS, METHS (18501); INTEGUMENT SYST-PHYSIOL, BIOCHEM (*18504); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-CARDIOVASC SYST (*22010); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: MURIDAE (86375)

Y017005 31 
80093259
CONTROLLED RELEASE TECHNOLOGY FOR THE CONTROL OF HELMINTHS IN RUMINANTS
ANDERSON N
CSIRO, DIV. ANIMAL HEALTH, ANIMAL HEALTH DES. LAB., PRIVATE BAG NO. 1, P.O., PARKVILLE, VIC. 3052, AUSTRALIA.
VET PARASITOL 18 (1). 1985. 59-66. CODEN: VPARD
Lang.: Eng.
Release rates from controlled release devices are determined by the device itself and thus are accurate, reproducible and predictable, whereas, in general, prolonged or slow release systems are sensitive to environmental conditions. Diffusion and dissolution are the principal means of achieving controlled release. A diffusion system is specific for the active ingredient and release rate decreases proportionately to the square root of time because of a decreasing concentration gradient or an increasing diffusion path. In dissolution systems, the choice of matrix determines the rate of dissolution and release rates are linearly related to the area of dissolution which can be maintained constant. Consequently, this system has general application, a sharp cut-off point and can be used for > 1 ingredient simultaneously. Potential disadvantages of controlled release technology center on unacceptable tissue residues and parasite resistance to the chemicals used. Advantages include the ability to program the release of compounds to achieve specific effects for various periods, decreasing the frequency of dosage and increasing the choice of compounds for the control of parasitic infections. Sufficient epidemiological information should be available before controlled release technology is implemented. Existing anthelmintics and control strategies can be used to achieve an enhanced, but expected result, e.g., prolonged reduction in pasture contamination to protect both ewes and lambs. In future it should be possible to devise compounds and strategies appropriate to the unique features of controlled release technology, e.g., compounds which interrupt or inhibit the growth and development of parasites. Environmental impact should be low because of the specific effect and low dosage of the chemical used.
Desc.: DIFFUSION DISSOLUTION SLOW RELEASE SYSTEM ENVIRONMENTAL IMPACT ANTIHELMINTHICS DRUG DELIVERY SYSTEM
Concept Codes: MATHEMATIC BIOL/STATISTIC METH (04500); BIOPHYS-BIOENGINEERING (*10511); BIOPHYS-BIOCYBERNETICS (10515); PATHOLOGY-THERAPY (12512); PHARMACOL-GENERAL STUDIES (*22002); DEVELOPMNTL BIOL-GEN MORPHGENSIS (25508) VETERINARY SCI-PATHOLOGY (*38004); CHEMOTHERAPY-ANTIPARASITIC AGNTS (*38510) PARASITOLOGY-VETERINARY (*60506); INVERTB PHYSIOL-GENERAL STUDIES (64001)
Biosystematic Codes: BOVIDAE (85715)

Y017005 32 
80089420
TREATMENT OF ANOVULATION BY PULSATILE ADMINISTRATION OF LHRH
THOMAS D; L'HERMITE M
SERVICE DE GYNECOLOGIE-OBSTETRIQUE, ULB, HOPITAL UNIVERSITAIRE BRUGMANN, BRUXELLES.
REV MED BRUX NOUV SER 6 (5). 1985. 325-333. CODEN: RMBRD
Lang.: FRENCH
A new means of treating anovulation by pulsatile administration of LHRH with use of a portable pump was tested. The study included 11 longstanding infertile patients, of which 10 presented central, hypothalamic anovulation that was proven (or supposed to be) resistant to clomifene; the 11th patient showed recurrent luteal insufficiency. LHRH was administered s.c. at 2.3-21 .mu.g doses every 90 min until echographic rupture of the dominant follicle, the luteal phase being supported by HCG [human chorionic gonadotropin] administration. Ovulation did indeed occur in 14 of the 17 treated cycles, during which no hyperstimulation could be clinically detected. Four pregnancies (including 1 chemical pregnancy) were obtained during such treatment; 2 additional pregnancies occurred during a clomifene-treated cycle, following immediately the 1st LHRH-treated cycle. Thus, pulsatile LHRH administration via a portable pump represents a valid alternative to the use of gonadotropins for ovulation induction; it requires only a minimal monitoring, with few risks of hyperstimulation.
Desc.: HUMAN CLOMIPHINE FERTILITY-DRUG HORMONE-DRUG
Concept Codes: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-STEROLS, STEROIDS (10067); PATHOLOGY-THERAPY (*12512); METABOLISM-STEROLS, STEROIDS (*13008); METABOLISM-PROTNS, PEPTDS, AM ACDS (*13012); REPRODUCT SYST-PHYSIOL, BIOCHEM (*16504); REPRODUCT SYST-PATHOLOGY (*16506); ENDOCRINE SYST-GONADS, PLACENTA (*17006); ENDOCRINE SYST-NEUROENDOCRINOLOG (*17020); INTEGUMENT SYST-GENL STUDS, METHS (18501); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504); NERVOUS SYST-PATHOLOGY (*20506); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028) ROUTES OF IMMUNIZ, INFECT, THERAP (22100); TOXICOL-PHARMACOLOGICAL (*22504)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 33 
80089163
INTRAVAGINAL CONTROLLED ADMINISTRATION OF FLUOROGESTONE ACETATE 4. IN-VITRO-IN-VIVO CORRELATION FOR INTRAVAGINAL DRUG DELIVERY FROM RATE-CONTROL VAGINAL PESSARY
KABADI M; CHIEN Y M
CONTROLLED DRUG DELIVERY RESEARCH CENTER, COLLEGE OF PHARMACY, RUTGERS UNIV., P.O. BOX 789, BUSCH CAMPUS, PISCATAWAY, NEW JERSEY 08854.
DRUG DEV IND PHARM 11 (6-7). 1985. 1313-1362. CODE: DDIPD
Lang.: Eng.
Sheep (150) received various types of Rate-Control vaginal pessaries for a period of up to 19 days at various geographic locations. As predicted from the in vitro studies, a constant (Q-t [quantity of drug released vs. time]) absorption profile was also observed in vivo. The effect of the loading dose of flurogestone acetate on the in vitro and in vivo absorption profiles were examined and minimum effective loading dose was determined. An excellent in vitro-in vivo correlation was established, which permitted the prediction of the long-term (19-day) in vivo absorption profiles from a short-term (3-day) in vitro absorption study.
Desc.: SHEEP HORMONE-DRUG PHARMACOKINETICS
Concept Codes: BIOCHEM STUD-STEROLS, STEROIDS (10067); METABOLISM-STEROLS, STEROIDS (13008); REPRODUCT SYST-GENL STUDS, METHS (16501); ENDOCRINE SYST-GONADS, PLACENTA (*17006); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-ENDOCRINE SYST (*22016); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028) ROUTES OF IMMUNIZ, INFECT, THERAP (22100); IN VITRO STUDS-CELLULR, SUBCELL (32600)
Biosystematic Codes: BOVIDAE (85715)

Y017005 34 
80089162
INTRAVAGINAL CONTROLLED ADMINISTRATION OF FLUROGESTONE ACETATE 3. DEVELOPMENT OF RATE-CONTROL VAGINAL DEVICES
KABADI M; CHIEN Y M
CONTROLLED DRUG DELIVERY RESEARCH CENTER, COLLEGE OF PHARMACY, RUTGERS UNIV., P.O. BOX 789, BUSH CAMPUS, PISCATAWAY, NEW JERSEY 08854.
DRUG DEV IND PHARM 11 (6-7). 1985. 1271-1312. CODEN: DDIPD
Lang.: Eng.
A Rate-Control vaginal device was developed which overcomes the low bioavailability and unpredicted Q-t1/2 type release and absorption rate profiles of flurogestone acetate delivered by the currently marketed Syncro-Mate pessary. The in vitro release and vaginal absorption profiles from the Rate-Control vaginal deive were run simultaneously; a linear Q-t
[quantity of drug released vs. time] relationship was obtained with a significant improvement in bioavailability. A mathematical model was developed to correlate the in vitro drug release and the vaginal absorption profiles of flurgestone acetate from the vaginal devices. The design, development and the simultaneous release and absorption profiles of flurogestone acetate from this new vaginal device were outlined and discussed.
Desc.: HORMONE-DRUG PHARMACOKINETICS DRUG DELIVERY SYSTEM SYNCRO-MATE PESSARY
Concept Codes: MATHEMATIC BIOL/STATISTIC METH (04500); BIOCHEM STUD-STEROLS, STEROIDS (10067); BIOPHYS-BIOCYBERNETICS (10515); METABOLISM-STEROLS, STEROIDS (13008); REPRODUCT SYST-GENL STUDS, METHS (16501); ENDOCRINE SYST-GONADS, PLACENTA (*17006); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-ENDOCRINE SYST (*22016); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028); ROUTES OF IMMUNIZ, INFECT, THERAP (22100); IN VITRO STUDS-CELLULR, SUBCELL (32600)

Y017005 35 
80089161
SIMPLE EVALUATION METHOD OF INTRINSIC DIFFUSIVITY FOR MEMBRANE-MODERATED CONTROLLED RELEASE
TOJO K; SUN Y; GHANNAM M; CHIEN Y W
CONTROLLED DRUG-DELIVERY RESEARCH CENTER, RUTGERS UNIV., COLLEGE OF PHARMACY, PISCATAWAY, NEW JERSEY 08854.
DRUG DEV IND PHARM 11 (6-7). 1985. 1363-1372. CODEN: DDIPD
Lang.: Eng.
The effect of diffusion boundary layers in an in vitro membrane permeation system on the membane diffusivity of drugs was investigated based on the 3 layer model. A simple method for evaluating the intrinsic diffusivity through the membrane was developed and the intrinsic diffusivity of progesterone and testosterone through a silicone membrane were determined using this approach.
Desc.: PROGESTERONE TESTOSTERONE HORMONE-DRUG DRUG DELIVERY SYSTEM PHARMACOKINETICS
Concept Codes: ATHEMATIC BIOL/STATISTIC METH (04500); BIOCHEM STUD-STEROLS, STEROIDS (10067); ENDOCRINE SYST-GONADS, PLACENTA (*17006); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003) ; PHARMACOL-ENDOCRINE SYST (*22016); IN VITRO STUDS-CELLULR, SUBCELL (32600)

Y017005 36 
80083893
DESIGN AND IN-VITRO EVALUATION OF A CONTROLLED RELEASE DRUG DELIVERY SYSTEM OF SULFASOMIDINE
DAS S K; GUPTA B K
DIVISION PHARMACEUTICS, FACULTY OF ENGINEERING AND TECHNOLOGY, DEPARTMENT OF PHARMACY, JADAVPUR UNIV., CALCUTTA-700 032, INDIA.
DRUG DEV IND PHARM 11 (8). 1985. 1621-1638. CODEN: DDIPD
Lang.: Eng.
A controlled release oral drug delivery system of Sulfasomidine [an antibacterial drug] was developed by spray congealing micropelleting technique using gelatin as the embedding matrix. The pellets were hardened by treating with Formalin-Isopropanol mixture. The in vitro release rate studies of Sulfanomidine from the micropelleted dosage form revealed that the drug release can be prolonged up to 8 h and not more than 39% of the embedded drug released in the 1st h of the in vitro dissolution study. The in vitro release patterns correlated with the reported in vivo studies. The method of formulation was optimized.
Desc.: ANTIBACTERIAL-DRUG DISSOLUTION
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064);  DENTAL/ORAL BIOL-GENL STUD, METHS (19001); PHARMACOL-GENERAL STUDIES (*22002); ROUTES OF IMMUNIZ, INFECT, THERAP (22100); IN VITRO STUDS-CELLULR, SUBCELL (32600); CHEMOTHERAPY-ANTIBACTERIAL AGNTS (*38504)

Y017005 37 
80082995
PH-BASED ENZYME POTENTIOMETRIC SENSORS 3. PENICILLIN-SENSITIVE FIELD EFFECT TRANSISTOR
CARAS S D; JANATA J
DEPARTMENT OF BIOENGINEERING, UNIV. OF UTAH, SALT LAKE CITY, UTAH 84112.
ANAL CHEM 57 (9). 1985. 1924-1925. CODEN: ANCHA
Lang.: Eng.
A diffusion-kinetic model for penicillin enzyme field effect transistor was developed and solved numerically. The external buffer plays a critical role in the response of this device. The 2nd weakly acidic group in the penicillioic acid affects the response characteristics, namely, at the high substrate concentrations.
Desc.: PENICILLOIC-ACID CLINICAL DRUG LEVELS BIOSENSOR BIOTECHNOLOGY
Concept Codes: CLIN BIOCHEM-GENL STUDIES (*10006); BIOCHEM METH-GENERAL (*10050); BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-GENERAL BIOPHYS TECH (*10504); BIOPHYS-BIOENGINEERING (*10511); ENZYMES-METHODS (*10804); PHARMACOL-DRUG METAB, METAB STIMU (*22003); CHEMOTHERAPY-GEN STUD, METH, METAB (*38502)

Y017005 38 
80079823
USE OF INDERAL FOR PREVENTING HEART DAMAGE IN MECHANICAL ASPHYXIA ATTENDED BY CLINICAL DEATH
DOLGIKH V T
CENT. RES. LAB., OMSK MED. INST., OMSK, USSR.
PATOL FIZIOL EKSP TER 10 (1). 1985. 18-23. CODEN: PAFEA
Lang.: RUSSIAN
In experiments on isolated isovolumically contracting rat hearts resuscitated after 8-min mechanical asphyxia the early postasphyxial period is marked by depression of myocardial contractile function and diminished efficacy of myocyte membrane Ca pump, which was demonstrated in induced high frequency of contractions. The exit of some enzymes (creatine phosphokinase, aspartate aminotransferase, lactate and malate dehydrogenases and RNase) from the cardiomyocytes into the coronary channel increased 2-fold and more. The factors underlying the depression of contractile function in the postasphyxial period are evidently disorders of bioenergetics, manifested by reduced content of creatine phosphate, ATP and glycogen in the myocardium and an excess of free fatty acids. Mechanical asphyxia considerably reduces heart resistance to hypoxia. Preliminary injection of the .beta.-blocking agent propranolol reduced lethality in the early restorative period to < 1/2 considerably reduced myocardial damage appraised according to the exit of enzymes into the coronary channel and prevented disorders of myocardial contractile function.
Desc.: RAT CARDIOVASCULAR-DRUG ENZYME CONTRACTILITY
Concept Codes: CYTOLOGY/CYTOCHEM-ANIMAL (*02506); BIOCHEM-GASES (*10012); BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-MEMBRANE PHENOMENA (*10508); EXTERN EFF-PHYSICAL, MECH EFFECTS (10612); ENZYMES-PHYSIOLOGICAL STUDIES (*10808); METABOLISM-PROTNS, PEPTDS, AM ACDS (*13012); CARDIOVASC SYST-HEART PATHOLOGY (*14506); RESPIRATORY SYST-GENL STUD, METHS (*16001); RESPIRATORY SYST-PATHOLOGY (*16006); PHARMACOL-CARDIOVASC SYST (*22010)
Biosystematic Codes: MURIDAE (86375)

Y017005 39 
80079028
HEPATIC FALCIFORM ARTERY ANATOMY ANGIOGRAPHIC APPEARANCE AND CLINICAL SIGNIFICANCE
WILLIAMS D M; CHO K J; ENSMINGER W D; ZIESSMAN H A; GYVES J W
DEP. RADIOL., BOX 13, UNIV. HOSP., ANN ARBOR, MICH. 48109.
RADIOLOGY 156 (2). 1985. 339-340. CODEN: RADLA
Lang.: ENG.
Three patients developed supraumbilical skin rashes during hepatic artery infusion chemotherapy [for liver cancer] by a surgically placed perfusion catheter and drug-infusion pump. In 1 patient, hepatic arterial scintigraphy with 99mTc macroaggregated serum albumin showed increased uptake corresponding to the rash, and  hepatic arteriogram showed a dilated falciform branch of the left hepatic artery. Surgical ligation of the falc form artery permitted further treatment without recurrent rash. Based on a review of 100 celiac arteriogram, the incidence of the falciform artery on angiographic studies is .apprx. 2%. The angiographic appearance of this artery is presented, and its potential clinical significance in hepatic artery perfusion chemotherapy is discussed.
Desc.: HUMAN CHEMOTHERAPY SUPRAUMBILICAL SKIN RASH LIVER CANCER
Concept Codes: PHOTOGRAPHY-METHS, MATLS, APPARAT (01012); RADIATION BIOL-RADTN, ISOTOP TECH (06504); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); ANATOMY/HISTOL-SURGERY (*11105); ANATOMY/HISTOL-RADIOLOGIC (11106); PATHOLOGY-THERAPY (12512); DIGESTIVE SYS-PATHOLOGY (*14006); CARDIOVASC SYST-GENL STUDS, METHS (14501); CARDIOVASC SYST-ANATOMY (14502); CARDIOVASC SYST-BLD  VESS PATHOL (*14508); INTEGUMENT SYST-PATHOLOGY (*18506); NEOPLSMS/NEOPL AGNTS-THERAP, AGNT (*24008)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 40 
80073864
APPLICATION OF THE PRINCIPLE OF LINKED FUNCTIONS TO ATP-DRIVEN ON PUMPS KINETICS OF ACTIVATION BY ATP/e
REYNOLDS J A; JOHNSON E A; TANFORD C
DEPARTMENT PHYSIOLOGY, DUKE UNIV. MEDICAL CENTER, DURHAM, N.C. 27710.
PROC NATL ACAD SCI U S A 82 (11). 1985. 3658-3661. CODEN: PNASA
Lang.: Eng.
If a ligand binds with unequal affinity to 2 distinct states of a protein, then the equilibrium between the 2 states becomes a function of the concentration of the ligand. A necessary consequence is that the ligand must also affect the forward and/or reverse rate constants for transition between the 2 states. For an enzyme or transport protein with such a transition as a slow step in the catalytic cycle, the overall rate also becomes a function of ligand concentration. These conclusions are independent of whether or not the ligand is a direct participant in the reaction. If it is a direct participant, then the kinetic effect arising from the principle of linked functions is distinct from the direct catalytic effect. These principles suffice to account for the biphasic response of the hydrolytic activity of ATP-driven ion pumps to the concentration of ATP, without the need to invoke > 1 ATP binding site per catalytic center.
Concept Codes: BIOCHEM STUD-NUCL ACD, PURNS, PYRM (10062); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); MINERALS (10069); BIOPHYS-MEMBRANE PHENOMENA (*10508); MOVEMENT (12100); MINERALS (*13010); METABOLISM-PROTNS, PEPTDS, AM ACDS (*13012); METABOLISM-NUCL ACD, PURINS, PYRIM (*13014)

Y017005 41 
80070845
EPIDURAL ANALGESIA IN OBSTETRICS USING AN ELECTRONIC SYRINGE
LAVINAC G; NOURY D; GRALL J Y; LE BERVET J Y
SERVICE D'ANESTHESIE-REANIMATION, HOP. SUD, 16 BOULEVARD DE BULGARIE,  B.P. 22129, F 35022 RENNES CEDEX.
J GYNECOL OBSTET BIOL REPROD 14 (2). 1985. 239-245. CODEN: JGOBA
Lang.: FRENCH
A study of 20 cases of epidural obstetrical analgesia is presented. A Bupivicaine-Fentanyl mixture was given by continuous flow to bring about this analgesia. After an initial injection of 10 ml (9 ml of 0.25% Bupivicaine and 0.05 mg Fentanyl), a mixture of 45 ml of 0.25% Bupivicaine and 0.25 mg Fentanyl was perfused into the epidural space using an electronic pump syringe, delivering at a rate of 5 ml/hr. The mean time of analgesia until the delivery is 4 h 40 min and the women in labor received a mean of 31.14 ml of 0.25% Bupivicaine (77.85 mg) and 0.173 mg Fentanyl. It took only 5 1/2 min to set up this form of analgesia. Not a single patient had any pain in the 1st stage of labor nor in the 2nd stage and 95% of them were able to push efficiently. There are no detectable changes in the hemodynamic parameters in either the mothers or the fetuses and no depression of maternal respiration was found. In each case the Apgar score was 10 after 5 min. The use of an electronic pump syringe to deliver a Bupivicaine-Fentanyl mixture in obstetrical labor is a great improvement in analgesia without any secondary effects in the mother and child
Desc.: HUMAN BUPIVACAINE FENTANYL ANALGESIC-DRUG
Concept Codes: BIOCHEM STUD-GENERAL (10060); PATHOLOGY-THERAPY (*12512); CARDIOVASC SYST-PHYSIOL, BIOCHEM (*14504); RESPIRATORY SYST-PHYSIOL, BIOCHEM (*16004); REPRODUCT SYST-PHYSIOL, BIOCHEM (*16504); NERVOUS SYST-PATHOLOGY (*20506); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-NEUROPHARMACOLOGY (*22024); DEVELOPMNTL BIOL-GENL, DESCRIPTIVE (*25502)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 42 
80070787
CONTROLLED RELEASE OF ISONICOTINIC-ACID HYDRAZIDE FROM THE MEMBRANE-COATED TABLET
KIM K M; KIM S K
COLL. PHARMACY, SEOUL NATIONAL UNIV., SEOUL 151, KOREA.
ARCH PHARMACAL RES (SEOUL) 8 (1). 1985. 7-14. CODEN: APHRD
Lang.: Eng.
Membrane-coated tablet of isonicotinic acid hydrazide (INAH), which releases INAH at the zero-order kinetics, was developed. It consisted of a soluble tablet core surrounded by a porous membrane which controls the diffusion rate. Tablet core were prepared by compressing granules of INAH and polyvinyl pyrrolidone (PVP). The cores were coated by polyvinyl chloride (PVC) dissolved in methyl ethyl ketone in which micronized sucrose were suspended. Diffusion rate of INAH from the tablet through the membrane was constant until the loaded INAH in the core was almost released. The rate was independent of pH of the dissolution medium. Water-soluble sucrose particles behaved as a poreproducing material in the water-insoluble PVC film coat. The pH independency of the rate was probably due to the high solubility of INAH in the water of wide pH range. The diffusion rate of INAH could be controlled by changing the composition of the membrane or the coat weight. This membrane-coated INAH tablet seemed to be a powerful condidate for the controlled release drug delivery system (DDS) of INAH or other highly water-soluble drugs.
Desc.: POLYVINYLPYRROLIDONE POLYVINYL CHLORIDE DRUG DELIVERY SYSTEM PHARMOCOKINETICS
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOPHYS-MOLECUL PROP, MACROMOLEC (10506); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003)

Y017005 43 
80070685
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY GEL-FILTRATION OF INSULIN DURING SHORT AND LONG TIME INFUSION BY ARTIFICIAL DELIVERY SYSTEMS
SCHRADER E; PFEIFFER E F
ABTEILUNG FUER INNERE MEDIZIN I DER UNIVERSITAET ULM, KUNSTLICHES PANKREAS, STEINHOVELSTR. 9, 7900 ULM, GERMANY.
J LIQ CHROMATOGR 8 (6). 1985. 1121-1138. CODEN: JLCHD
Lang.: Eng.
The aggregational behavior of insulin during application by artificial delivery systems was examined with high performance liquid chromatography [HPLC]. The short time infusion was performed by an autosyringe pump and the long time infusion was performed by a Siemens pump. For comparison samples of about 1 ml were collected and the radioimmunological activity was determined to verify the results of the HPLC gel-filtration. The chromatograms, performed at 37.degree. C and at ambient temperature, showed no aggregates of a higher MW. Sedimentation only once was observed during long time infusion, the immediately performed gel-filtration surprisingly showed at no time an aggregate of a higher MW but the quantity of insulin was obviously reduced. A different length of the catheter systems used did not promote the aggregational behavior. The absorbed quantity of insulin depends on the length of the catheter system used. The material of the catheters was polyethylene.
Desc.: ANTIDIABETIC-DRUG DRUG DELIVERY SYSTEM
Concept Codes: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); PATHOLOGY-THERAPY (*12512); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-ENDOCRINE SYST (*22016)

Y017005 44 
80070444
THE IMMEDIATE EFFECTS OF ISOSORBIDE DINITRATE ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH ACUTE HYPOXEMIC RESPIRATORY FAILURE A COMBINED INVASIVE AND RADIONUCLIDE STUDY
SIBBALD W J; SHORT A I K; DRIEDGER A A; WELLS G A
DEP. MED., VICTORIA HOSPITAL, P.O. BOX 54375, LONDON, ONT., CAN. N6A 4G5.
AM REV RESPIR DIS 131 (6). 1985. 862-868. CODEN: ARDSB
Lang.: Eng.
Isosorbide dinitrate (20 mg) was administered sublingually to 16 patients with acute hypoxemic respiratory failure (ARF) complicated by pulmonary artery hypertension (PAH) and evaluated its effects 20-30 min later using a combination of invasively measured pressures and flows and ECG-gated cardiac scintigraphy. The right and left ventricular ejection fractions and a simultaneous thermodilution stroke volume index were measured and the respective end-diastolic (EDVI) and end-systolic (ESVI) volume indexes were calculated. An initially depressed mean right ventricular ejection fraction (RVEF) increased modestly after the administration of isosorbide dinitrate (35 .+-. 10 to 41 .+-. 10%; P < 0.02), whereas both the mean right ventricular end-diastolic (-27 .+-. 50 ml m2; P < 0.04) and end-systolic (-27 .+-. 44 ml/m2; P < 0.03) volume indexes fell. The RVEF increased in 11 of 16 patients; within this subgroup, a decrease in the RVEDVI and RVESVI was associated with a decrease in both cardiac index (.DELTA. 0.3 l/min/m2) and LVEDI (.DELTA. -15 .+-. 21 ml/m2; P < 0.01); hence, O2 delivery also fell (.DELTA.-36 .+-. 56 ml/min/m2; P < 0.05). In some patients with ARF complicated by PAH, sublingually administered nitrates may improve right ventricular systolic function when globally depressed. Left ventricular pump function appears to be depressed when a concurrent depression in right ventricular pump function ensues.
Desc.: ANTIHYPERTENSIVE-DRUG ELECTROCARDIOGRAPHY SCINTIGRAPHY PULMONARY ARTERY HYPERTENSION
Concept Codes: PHOTOGRAPHY-METHS, MATLS, APPARAT (01012); RADIATION BIOL-RADTN, ISOTOP TECH (06504); BIOCHEM-GASES (*10012); BIOCHEM STUD-GENERAL (10060); ANATOMY/HISTOL-RADIOLOGIC (*11106); PATHOLOGY-DIAGNOSTIC (*12504); CARDIOVASC SYST-GENL STUDS, METHS (*14501); CARDIOVASC SYST-BLD VESS PATHOL (*14508); RESPIRATORY SYST-GENL STUD, METHS (*16001); RESPIRATORY SYST-PATHOLOGY (*16006); PHARMACOL-CLINICAL PHARMACOL (22005); PHARMACOL-CARDIOVASC SYST (*22010)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 45 
80061753
BACTERIOLOGIC ASPECTS AND STABILITY OF DRUGS DURING EPIDURAL LONG-TERM INFUSION WITH IMPLANTED OR EXTERNAL PUMPS
MUELLER H; BISCOPING J; GIPS H; TILKES F; STRUNZ P; HEMPELMANN G
ABT. FUER ANAESTHESION. UND OPERATIVE INTENSIVMED., KLINIKUM DER JUSTUS LIEBIG-UNIV., KLINIKSTR. 29, D-6300 GIESSEN.
ANAESTHESIST 34 (5). 1985. 247-251. CODEN: ANATA
Lang.: GERMAN
Implantable devices (implanted pump/implanted catheter and port) are recommended for continuous epidural application of opiates or local anesthetics in order to reduce hygienic problems during long term epidural medication. No signs of contamination could be found during bacteriologic culture of residual volumes of 30 patients treated with epidural drug delivery systems and of samples collected during an in vitro investigation (incubation of filled external pump systems at body temperature, storage of syringes with a premixed solution of opiate and local anesthetic for repeated epidural bolus application). As demonstrated in a case report prophylactic antibiotic coverage prior to implantation may be necessary in patients with a preexisting susceptibility to infection. The concentrations of morphine (radioimmunoassay) and of bupivacaine (gas-solid chromatography) within the reservoir were stable during clinical therapy and during the in vitro experiments.
Desc.: HUMAN LOCAL ANESTHETICS OPIATES MORPHINE BUPIVACAINE CONTAMINATION IMPLANTED CATHETER AND PORT DRUG DELIVERY DEVICE PROPHYLACTIC ANTIBIOTIC COVERAGE
Concept Codes: BIOPHYS-GENERAL BIOPHYS TECH (10504); BIOPHYS-BIOENGINEERING (*10511); EXTERN EFF-TEMPERATURE (10614); NERVOUS SYST-PHYSIOL, BIOCHEM (20504); PHARMACOL-GENERAL STUDIES (22002); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-NEUROPHARMACOLOGY (*22024); ROUTES OF IMMUNIZ, INFECT, THERAP (2210); IMMUNOL/IMMUNOCHEM-GEN METH (34502); MED/CLIN MICROBIOL-BACTERIOLOGY(*36002); PUB HEALTH-INANIMATE DIS VECTORS (*37060); PUB HEALTH MICROBIOL (37400); CHEMOTHERAPY-ANTIBACTERIAL AGNTS (38504); PLANT PHYSIOL-CHEM CONSTITUENTS (51522); PHARMACOGNOSY/PHARMACEUT BOTANY (54000)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 46 
80061553
INFLUENCE OF GLUCOCORTICOID AND BETAMIMETIC THERAPY ON MILK SECRETORY IMMUNOGLOBULIN A CONCENTRATION PRODUCED BY MOTHERS DELIVERING PRETERM INFANTS
MARTELL M; OEHNINGER C; SCOTTI C; DELGADO L; MARTINEZ M; KORC 
CENT. LATINOAMERICANO PERINATOL. DESARROLLO HUMANO, CASILLA DE CORREO 627, MONTEVIDEO, URUGUAY.
J PERINAT MED 13 (2). 1985. 61-65. CODEN: JPEMA
Lang.: Eng.
A prospective study was performed to find the possible difference in secretory IgA concentration in milk from mothers with term pregnancy and those delivering at earlier gestational ages. Since tocolytgic drugs and/orglucocorticoid agents are usually given in cases of threatened premature labor, the preterm group was divided into mothers with or without medication. Mothers (32) were distributed in 3 groups: group I, mothers with preterm labors without any medication; group II, preterm labors with previous treatment with betamimetics and glucocorticoids and group III, term labors. In each of the 3 groups, three periods were studied: colostral (4 to 5 days postpartum), transitional (8 to 10 days), and mature (14 50 15 days). All mothers were healthy, with good nutritional state, without local inflammation and having membranes that had ruptured 12 h or less before labor. There was no significant difference in the proportion of primiparas and multiparas in both groups. The gestational age was evaluated by amenorrhea and neonatal examination. In all mothers milk was extracted with a vacuum pump to empty the mammary gland. The determinations were made using a specific antibody against the secretory component. The concentration of the free secretory component in these milks was practically insignificant. No differences were found in the concentration of secretory IgA among the 3 groups in the periods that were studied, colostral, transitional or mature. The greater the period of the between labor and milk extraction, there was a progressive decrease in the concentration of secretory IgA. No evidence was found showing that medication given to the mother during the hours before delivery affects the concentration of secretory IgA in milk. This knowledge, together with information previously described regarding composition of preterm mother's milk, supports the statement that preterm neonates may be fed with their own mother's milk.
Desc.: HORMONE-DRUG TOCOLYTIC AGENTS PREMATURE LABOR
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINOACD (10064); BIOCHEM STUD-STEROLS, STEROIDS (10067); BIOCHEM STUD-CARBOHYDR. (10068); BLOOD/BODY FLDS-OTHER BODY FLDS (*15010); REPRODUCT SYST-GENL STUDS, METHS (*16501); REPRODUCT SYST-PHYSIOL, BIOCHEM (*16504); ENDOCRINE SYST-ADRENALS (*17004); PHARMACOL-ENDOCRINE SYST (*22016); PHARMACOL-REPRODUCT SYST, IMPLANT (*22028); DEVELOPMNTL BIOL-PATHOLOGICAL (*25503); IMMUNOL/IMMUNOCHEM-GEN METH (*34502)
Biosystematic Codes: BOVIDAE (85715)

Y017005 47 
80061552
MODERATE INTAKE OF SUCROSE DOES NOT IMPAIR METABOLIC CONTROL IN PUMP-TREATED DIABETIC OUT-PATIENTS 
CHANTELAU E A; GOESSERINGER G; SONNENBERG G E; BERGER M
DEP. MED., DUESSLDORF UNIV., MOORENSTR. 5, D-4 DUESSELDORF 1, FRG.
DIABETOLOGIA 28 (4). 1985. 204-207. CODEN: DBTGA
Lang.: Eng.
The effects of dietary intake of sucrose vs. the use of sodium cyclamate were studied in 10 Type 1 (insulin-dependent) diabetic patients on continuous s.c. insulin infusion therapy. After a 4 wk run-in period, the patients were randomly assigned to a cross-over protocol with two 4 wk periods during which they used sucrose or sodium-cyclamate as sweetener. During the experimental periods, 24 .+-. 13 g/day sucrose and 348 .+-. 270 mg/day of sodium cyclamate were consumed, respectively. Metabolic control was monitored by the patients performing blood glucose self-monitoring several times daily. Bi-weekly, all patients were followed-up in the outpatient clinic. Mean daily blood glucose concentrations, as well as the average daily insulin dose, did not differ between the 3 experimental periods. HbAIc-levels, serum lipids and body wt remained unchanged and within the normal ranges throughout the study. Moderate dietary intake of sucrose did not affect metabolic control in these normal weight, near-normoglycemic, normolipidemic, pump-treated Type 1 diabetic patients during a 1-mo. period. Whether similar conclusions apply to less well controlled diabetic patients remains to be seen.
Desc.: INSULIN ANTIDIABETIC-DRUG
Concept Codes: BIOCHEM STUD-PORPHYRNS, BILE PIGM (10065); BIOCHEM STUD-LIPIDS (10066); BIOCHEM STUD-CARBOHYDR. (10068); PHYSIOLOGY-GENERAL STUDIES (*12002); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-LIPIDS (*13006); METABOLISM-PORPHYRINSIBILE PIGMN (13013); METABOLISM-METABOLIC DISORDERS (*13020); NUTRITION-CARBOHYDRATES (*13220); BLOOD/BODY FLDS-BLOOD, -LYMPH STUD (15002); ENDOCRINE SYST-PANCREAS (*17008); INTEGUMENT SYST-GENL STUDS, METHS (18501); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 48 
80061547
ABSORPTION OF SUBCUTANEOUSLY ADMINISTERED REGULAR HUMAN AND PORCINE
INSULIN IN DIFFERENT CONCENTRATIONS
CHANTELAU E; SONNENBERG G E; RAJAB A; ROEMISCH J; BERGER M
II. MED. KINIK E; UNIV. DUESSELDORF, MOORENSTRASSE 5, D-4000 DUESSELDORF, FRG.
DIABETE METAB 11 (2). 1985. 106-110. CODEN: DIMED
Lang.: Eng.
The influence of the insulin concentration on its absorption from the subcutaneous tissues was studied by direct measurement of the appearance of insulin in the circulation after its s.c. administration. Ten units of regular insulin of semisynthetic human and porcine origin in strength of 15 units/ml, ?0 units/ml and 100/units/ml were administered as bolus to 9 healthy male volunteers, using switched-off, manually handled insulin pumps. Insulinemia rose significantly higher (P < 0.05) and insulin levels peaked earlier after the delivery of the 15 units/ml insulin solutions compared to the 100 units/ml insulin solutions. These findings might be of interest for type-I diabetic patients using insulin pumps that are to be loaded with regular insulin in varying concentrations.
Desc.: ANTIDIABETIC-DRUG INSULINEMIA INSULIN PUMP TYPE I DIABETES
Concept Codes: BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); PATHOLOGY-THERAPY (*12512); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-PROTNS, PEPTDS, AM ACDS (*13012); METABOLISM-METABOLIC DISORDERS (*13020); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (1?002); INTEGUMENT SYST-GENL STUDS, METHS (18501); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYS (*22016); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 49 
80061340
CLINICAL RESULTS OF INTRA-AORTIC BALLOON PUMPING IN 51 PATIENTS FOLLOWING CARDIAC SURGERY
OKAMURA T; AMANO J; NUKARYA M; OZEKI M; WATANABE M; HIROOKA Y; OHSE Y; SUNAMORI M; TANAKA A; SUZUKI A
DEP. OF THORACIC CARDIOVASCULAR SURGERY, TOKYO, JAPAN.
J JPN ASSOC THORAC SURG 33 (3). 1985. 291-297. CODEN: NKZAA
Lang.: JAPANESE
IABP [intra-aortic balloon pumping] for perioperative low cardiac output syndrome (LOS) and the linger period of IABP with or without concomitant use of myocardial protective agents such as lidocaine, coenzyme Q10 (CoQ10) and aprotinin on complications and survival rate were examined. Adult patients (51) who developed left ventricular failure folowing various cardiac surgery were subjected in this investigation. Eight patients died of LOS because of unsuccessful weaning from IABP. Only 2 patients died in the hospital because of respiratory failure and nonoliguric renal failure but no hospital deaths were noted in relation to LOS in the survival patients. Survival rate was as follows: 67% in the cases treated with IABP at emergency operation for cardiogenic shock, 77% in the patients who were unable to be weaned from cardiopulmonary bypass (CPB) and 79% in the patients who were weaned from CPB but needed IABP for treatment of LOS. The duration of IABP support was 1-28 days (mean 5.3 days) in survivors from IABP but only 3 patients (7%) sustained complications related to use of the IABP. There was no significant correlation between the incidence of complications and duration of IABP support. The longer period of IABP support appears to be mandatory without raising the frequency of complications. Fifty-one patients were divided into 2 groups. Group I (30 patients) was treated by IABP only and group II (21 patients) was treated by the concomitant use of lidocaine, coenzyme Q10 and aprotinin with IABP. Lidocaine was infused continuously 1-2 mg/min, aprotinin and CoQ1 were administrated 5000-10, 000 kU/kg per day and 5-10 mg/day, respectively. Successful weaning rate from IABP was 95% (20/21) in group II and was higher than that of 77% (23/30) in group I. There were no significant differences in parameters between 2 groups concerning the preoperative and postoperative factors except a lower rectal temperature. Concomitant use of lidocaine, CoQ1o and aprotinin with IABP leads to an improvement in postoperative LOS.
Desc.: LIDOCAINE COENZYME Q-10 APROTININ CARDIOVASCULAR-DRUG RESPIRATORY FAILURE NONOLIGURIC RENAL FAILURE SURVIVAL RATE LOW CARDIAC OUTPUT SYNDROME PHARMACOKINETICS
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-GENERAL BIOPHYS TECH (10504); ENZYMES-GEN, COMPAR STUD, COENZYMS (*10802); ANATOMY/HISTOL-SURGERY (11105); PATHOLOGY-NECROSIS (12510); PATHOLOGY-THERAPY (12512); CARDIOVASC SYST-GENL STUDS, METHS (*14501); CARDIOVASC SYST-HEART PATHOLOGY (*14506); CARDIOVASC SYST-BLD VESS  PATHOL (*14508); URIN SYST/EXT SECR-PATHOLOGY (15506); RESPIRATORY SYST-PATHOLOGY (16006); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-CARDIOVASC SYST (*22010)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 50 
8006056
TREATMENT OF COLORECTAL CANCER HEPATIC METASTASES BY HEPATIC ARTERY CHEMOTHERAPY
COHEN A M; KAUFMAN S D; WOOD W C
COX BUILDING, MASS. GENERAL HOSPITAL, BOSTON, MASS. 02114.
DIS COLON RECTUM 28 (6). 1985. 389-393. CODEN: DICRA
Lang.: Eng.
Clinical experience with 69 patients with metastatic colorectal cancer to the liver treated with hepatic artery chemotherapy is reviewed. All patients have had a minimum of 6 mo. follow-up. The Infusaid implantable drug delivery system was used by direct laparotomy in 1/3, and via the transaxillary approach in the remaining 2/3. Two thirds of the patients had at least 25% of the liver replaced with tumor. Chemotherapeutic agents included FUdR [fluoro-2'-deoxyuridine] mitomycin C, and BCNU [1, 3-bis-2-chloroethyl-1-nitrosourea]. The overall response rate was 51% and 69% for the 3-drug combination. Efficacy was not different in patients who had received prior systemic fluorouracil. Median survival from start of hepatic artery chemotherapy was 1 yr.
Desc.: HUMAN FLUORO-2'-DEOXYURIDINE MITOMYCIN C 1 3 BIS-2-CHLOROETHYL-1-NITROSOUREA ANTINEOPLASTIC-DRUG DRUG-DRUG INTERACTION INFUSAID IMPLANTABLE DRUG DELIVERY SYSTEM DIRECT LAPAROTOMY TRANSAXILLARY APPROACH
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-NUCL ACD, PURNS, PYRM (10062); BIOPHYS-GENERAL BIOPHYS TECH (10504); BIOPHYS-BIOENGINEERING (*10511); DIGESTIVE SYST-PATHOLOGY (*14006); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-DIGESTIVE SYST (*22014); NEOPLSMS/NEOPL AGNTS-THERAP, AGNT (*24008)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 51 
80060306
PHASE I TRIAL OF AN IMPLANTED BATTERY-POWERED PROGRAMMABLE DRUG DELIVERY SYSTEM FOR CONTINUOUS DOXORUBICIN ADMINISTRATION
VOGELZANG N J; RUANE M; DEMEESTER T R
SECT. HEMATOL./ONCOL., 5841 S. MARYLAND AVE., BOX 420, CHICAGO, ILL. 60637, USA.
J CLIN ONCOL 3 (3). 1985. 407-414. CODEN: JCOND
Lang.: ENG.
A 2nd generation, implantable drug administration device (DAD, Medtronic, Inc., Minneapolis [Minnesota, SA]) which contains a 20-ml drug reservoir, a lithium-thionylchloride battery, a peristaltic roller pump, a microprocessor circuit and an acoustic transducer has entered clinical trials. After surgical placement, drug is entered into and removed from the DAD percutaneously through a Silastic fill port using a standard gauge needle and syringe. The pump is noninvasively programmed, using a hand-held telemetry wand, to administer the drug in a continuous infusion, bolus, or bolus-delay mode. Because of the apparent improved therapeutic index of continuous-infusion doxorubicin (CID), a phase I trial of the Medtronic DAD with CID was begun. Thirteen pumps in 13 patients have functioned for a median of 153 days (range, 11-395 days), with 1 pump still functioning. Four pumps ceased function at 170, 278, 331 and 370 days, respectively; there was a catheter-tip clot on 1 of the pumps that later malfunctioned. All other pumps functioned until the death of the respective patients. In 84 pump refills, without drug extravasation, the median drug delivery error (actual residual vol-calculated residual vol/calculated residual vol .times. 100%) was 14%. Doxorubicin was compatible with all components of the drug pathway and did not significantly decompose during 2 wk in the drug reservoir. The starting dose of CID was 2.0 mg/m2 per d [day], and the maximum tolerated dose was 4.1 mg/m2 per d (range, 3.5-5.5). A median cumulative doxorubicin dose of 244 mg/m2 per patient (range, 10-583 mg/m2) has been infused. Stomatitis was dose limiting in 7 of 10 evaluable patients, and tumor regression occurred in 2 of 10 evaluable patients. The Medtronic DAD is a safe and reliable device that allows CID
Desc.: HUMAN ANTINEOPLASTIC-DRUG SURGICAL PLACEMENT MEDTRONIC DRUG ADMINISTRATION DEVICE PROGNOSIS STOMATITIS
Concept Codes: CYTOLOGY/CYTOCHEM-HUMAN (02508); BIOPHYS-GENERAL BIOPHYS TECH (*10504); BIOPHYS-BIOENGINEERING (*10511); ANATOMY/HISTOL-SURGERY (11105) ; PATHOLOGY-INFLAMMATN, INFLAM DIS (*12508); PATHOLOGY-NECROSIS (12510); PATHOLOGY-THERAPY (*12512); METABOLISM-METABOLIC DISORDERS (13020); DENTAL/ORAL BIOL-PATHOLOGY (*19006); PHARMACOL-CLINICAL PHARMACOL (*22005); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100); NEOPLSMS/NEOPL AGNTS-PATH, CLINIC (*24004); NEOPLSMS/NEOPL AGNTS-THERAP, AGNT (*24008)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 52 
80055866
COMPARATIVE RESPONSIVENESS OF THE RAPIDLY ACTING ARTERIAL PRESSURE CONTROL SYSTEM TO QUICK MILD HEMORRHAGE AND INFUSION IN CONSCIOUS RABBITS
HOSOMI H; MATSUDA S; MORITA H; NISHIDA Y; KOYAMA S
DEPARTMENT OF PHYSIOLOGY, KAGAWA MEDICAL SCHOOL, KAGAWA 761-07, JAPAN.
PFLUEGERS ARCH EUR J PHYSIOL 404 (1). 1985. 103-106. CODEN: PFLAB
Lang.: Eng.
The responsiveness of the rapidly acting arterial pressure control system to hemorrhage and infusion was investigated. Two catheters, one for pressure measurement and the other for inducing hemorrhage and infusion, were chronically implanted in 19 rabbits. A few days after the operation, each animal was quickly bled and transfused (2 ml/kg body wt) at intervals of 5 min while it was conscious. The hemorrhage-infusion experiment was repeated 16 times in each animal. The 16 strings of data were pooled for each animal. The overall open-loop gains (G) of the rapidly acting arterial pressure control system were estimated from the individually pooled responses to hemorrhage and infusion. There was no significant difference between the G-values, i.e., 7.2 .+-. 1.2 by hemorrhage and 7.1 .+-. 1.2 by infusion (mean .+-. SD), as evaluated by the paired t-test (P > 0.5). Thus, the responsiveness of the rapidly acting arterial pressure control system to quick mild hemorrhage and to infusion appears to be similar.
Desc.: OPEN-LOOP GAIN
Concept Codes: BIOPHYS-GENERAL BIOPHYS TECH (10504); BIOPHYS-BIOCYBERNETICS (*10515); ANATOMY/HISTOL-EXPERIMENTAL (111?4); CARDIOVASC SYST-GENL STUDS, METHS (14501); CARDIOVASC SYST-PHYSIOL, BIOCHEM (*14504); CARDIOVASC SYST-BLD VESS PATROL (*14508)
Biosystematic Codes: LEPORIDAE (86040)

Y017005 53 
80054198
AN INDWELLING CANNULA SYSTEM FOR THE PRIMATE EYE
MIKI K; PATTERSON R; RYAN S J
DEP. OPHTHALMOLOGY, UNIV. SOUTHERN CALIFORNIA SCH. MED., ESTELLE DOHENY EYE FOUNDATION, 1355 SAN PABLO ST., LOS ANGELES, CA 90033, USA.
J NEUROSCI METHODS 13 (3-4). 1985. 267-280. CODEN: JNMED
Lang.: Eng.
An indwelling cannula system was designed as an instrument for chronic drug infusion into the vitreous cavity and tested in the cynomolgus monkey eye with repeated injections or continuous infusion using a pumping device. The cannula was passed through the pars plana and its tip situated in the vitreous cavity close to the macular area. Clinical observations up to 18 mo. did not reveal any adverse effects due to implantation. Histopathological observations from 1 wk to 18 mo. after surgery revealed tissue proliferation around the cannula was minimal and localized only at the wound site, where proliferative tissue originated from the episclera and ciliary epithelium. Retina and choroid at the posterior pole showed normal morphology. Light microscopic autoradiograms demonstrated the function of this system. Injections of tritiated leucine through the cannula resulted in narrow bands of radioactive labeling of the photoreceptor outer segments corresponding to each injection. In contrast, chronic delivery using the pumping device resulted in a diffuse and wide band of labeling. These results strongly suggest that this system did not adversely affect the eye and that repeated intravitreal injections or chronic drug delivery into the vitreous are feasible using this system. Furthermore, autoradiographic results suggest that the drugs infused into the vitreous cavity spread readily into the retina.
Desc.: MONKEY CHOROID VITREOUS CAVITY RETINA MACULAR AREA PARS PLANA CHRONIC DRUG INFUSION PUMPING DEVICE
Concept Codes: PHOTOGRAPHY-METHS, MATLS, APPARAT (01012); RADIATION BIOL-RADTN, ISOTOP TECH (06504); BIOCHEM STUD-GENERAL (10060); BIOPHYS BIOENGINEERING (*10511); ANATOMY/HISTOL-RADIOLOGIC (*11106); SENSE ORGANS-GENL STUDS, METHS (*20001); SENSE ORGANS-ANATOMY (*20002); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: PRIMATES-UNSPECIFIED (86190)

Y017005 54 
80052669
A POSSIBLE PH-CONTROLLED DRUG DELIVERY SYSTEM BASED ON A DERIVATIVE OF THE POLYSACAHARIDE SCLEROGLUCAN
ALHAIQUE F; RICCIERI F M; SANTUCCI E; CRESCENZI V; GAMINI A
CATTEDRA DI TECNICA E LEGISLAZIONE FARMACEUTICA, ISTITUTO DI CHIMICA FARMACEUTICA, ROME, ITALY.
J PHARM PHARMACOL 37 (5). 1985. 310-313. CODEN: JPPMA
Lang.: Eng.
Four carboxylated derivatives of scleroglucan were obtained by oxidation, to different extents, of the glucopyranose side chains of the natural polysaccharide. The diffusion of model molecules through aqueous solutions of these new products was measured at various pH values. The reversible pH induced sol-gel transition of some of the polyelectrolyte solutions tested effects a remarkable variation in the diffusion rate of the permeating species; in this sense the most interesting polysaccharide appears to be the product with 70% oxidized glucopyranose moieties. The behavior of scleroglucan and its derivatives was compared with that of carboxymethylcellulose and the mechanism involved in drug permeation and release discussed. The possible application of 1 of the new products in controlled release formulations for oral use is also reported.
Desc.: HUMAN APPLICATION PHARMACEUTICAL ADJUNCT-DRUG ORAL
Concept Codes: BIOCHEM METH-CARBOHYDRATES (*10058); BIOCHEM STUD-CARBOHYDR. (*10068); BIOPHYS-GENERAL BIOPHYS TECH (10504); BIOPHYS-MOLECUL PRO?, MACROMOLEC (*10506); PATHOLOGY-THERAPY (12512); DENTAL/ORAL BIOL-GENL STUD, METHS (19001); PHARMACOL-GENERAL STUDIES (*22002) PHARMACOL-CLINICAL PHARMACOL (22005); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 55 
80052443
CLINICAL AND HEMODYNAMIC EFFECTS OF CONTINUOUS INTRAVENOUS INJECTION OF ISOSORBIDE DINITRATE IN PATIENTS WITH CONGESTIVE HEART FAILURE
ITOH M; INDEN M; NODA E; KAWAHIRA S; TANIMURA H; TAKASAKIH
DEP. INTERNAL MED., CARDIOL., UENO CITY, HOSP.
RESPIR CIRC 33 (5). 1985. 679-684. CODEN: KOJUA
Lang.: JAPANESE
The hemodynamic effects of isosorbide dinitrate [ISDN] administered by continuous i.v. infusion to 10 patients with refractory pump failure was studied. Patients entered the study only if mean pulmonary capillary wed?e pressure [PCWP] was > 20mm Hg and systolic arterial pressure 90mm Hg or above. The etiology was valvular heart disease in 5 patients, hypertensive and/or arterioscleotic heart disease in 3 patients, dilated cardiomyopathy in 1 patient and acute myocardial infarction in 1 patient. The initial dosage of 3mg/h was increased to the maintenance does until PCWP was reduced to 18 mm Hg or less. After 2 h injection of ISDN in a dose range of 5-8mg/hr mean PCWP decreased from 33 mm Hg to 15 mm Hg (P < 0.001), mean pulmonary arterial pressure 41 mm Hg to 23 mm Hg (P < 0.001), mean right atrial pressure 14 mm Hg to 5 mm Hg (P < 0.001). There were no deleterious effects on heart rate, blood pressure, cardiac index, stroke volume index, stroke work index, double product, systemic vascular resistance or pulmonary vascular resistance. But the change in cardiac index correlated positively with the initnal SVR levels (r=0.71, P < 0.01) and inversely with the control cardiac index (r= -0.85, P < 0.01). During these studies, the clinical signs of left ventricular failure disappeared in all patients and there was only one untoward effect of slight headache. I.v. ISDN is a potent vasodilator with acting as preload reduction and useful for the treatment of congestive heart failure as a deloading agent.
Desc.: CARDIOVASCULAR-DRUG VASODILATOR MYOCARDIAL INFARCTION ARTERIOSCLEROSIS HYPERTENSION VALVULAR HEART DISEASE
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOPHYS-GENERAL BIOPHYS TECH (10504); PATHOLOGY-DIAGNOSTIC (*12504); CARDIOVASC SYST-GENL STUDS, METHS (*14501); CARDIOVASC SYST-HEART PATHOLOGY (*14506); CARDIOVASC SYST-BLD VESS PATHOL (*14508); PHARMACOL-CLINICAL PHARMACOL (22005); PHARMACOL-CARDIOVASC SYST (*22010)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 56 
80052323
CORONAROTROPIC MEDICATIONS WITH GENERAL VASODILATOR ACTION IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
GHERASIM L; CINTEZA M; PARVU V; DOROBANTU M; BOGDAN M; DINULESCU D; POPEIA R; VASILESCU M
CLIN. MED. IV, SPITALUL CLIN. MUNICIPIULUI BUCURESTI.
REV MED INTERNA NEUROL PSIHIATR NEUROCHIR DERMATO-VENEROL SER MED INTERNA
36 (5). 1984 (RECD. 1985). 385-395. CODEN: RMIID
Lang.: ROMANIAN
The action of some nitrites (transdermal nitroglycerine and delayed isosorbide dinitrate.sbd.[isoket]) and molsidomine was studied in acute myocardial infarction patients with and without acute pumping dysfunction. Acute myocardial infarction patients (164) were subjects of the study, 52 of which had acute pumping dysfunction (Killip classes II, III, and IV) while 50 were in Killip class I. They received, in addition to the test drugs, analgesics, digitalis, and diuretics. Parameters studied included: clinical hemodynamic; the duration of pain; ECG, total glutaminic oxalacetic transaminase, the creatine phosphokinase curve; serum myoglobin, and the quantities of analgesics, digitalis, and diuretics. A rapid improvement of functional hemodynamics was observed in the transdermal nitroglycerin group. The number of branches which developed necroses was determined by ECG and was significantly reduced only in this group. Both forms of nitrites produced significant reduction of the duration of pain as well as of the quantity of analgesics.
Desc.: HUMAN NITROGLYCERIN DIGITALIS ISOSORBIDE DINITRATE ISOKET MOLSIDOMINE CARDIOVASCULAR-DRUG ANALGESICS DIURETICS PUMPING DYSFUNCTION CLASSIFICATION MYOGLOBIN HEMODYNAMICS PAIN ELECTROCARDIOGRAM GLUTAMIC-OXALACETIC TRANSAMINASE CREATININE PHOSPHOKINASE
Concept Codes: BIOPHYS-GENERAL STUDIES (10502); ENZYMES-PHYSIOLOGICAL STUDIES (*10808); PHYSIOLOGY-INSTRUMENTATION (12004); PATHOLOGY-THERAPY (*12512); CARDIOVASC SYST-PHYSIOL, BIOCHEM (14504); CARDIOVASC SYST-HEART PATHOLOGY (*14506); CARDIOVASC SYST-BLD VESS PATHOL (*14508); INTEGUMENT SYST-GENL STUDS, METHS (1?501); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-CARDIOVASC SYST (*22010); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 57 
80051972
HORIZONTAL OPTOKINETIC OCULAR NYSTAGMUS IN THE PIGMENTED RAT
HESS B J M; PRECHT W; REBER A; CAZIN L
INSTITUT FUR HIRNFORSCHUNG, UNIVERSITAT ZURICH, AUGUST-FIREL-STRASSE 1, CH-8029 ZURICH, SWITZERLAND.
NEUROSCIENCE 15 (1). 1985. 97-108. CODEN: NRSCD
Lang.: ENG.
Horizontal optokinetic nystagmus was elicited in rats by rotation of a pattern of bright dots projected onto a cylinder surrounding the animal. Eye position was measured with the electromagnetic search coil technique. Optokinetic stimuli consisted either of velocity steps of pattern rotation or sinusoidal oscillations. Closed-loop gain (slow phase eye velocity pattern velocity) of steady-stage step responses in binocular vision ranged between 0.8-1.0 for pattern velocities up to 20-40% and decreased thereafter. Open-loop gain (steady-state slow phase velocity retinal slip velocity) was dependent on retinal slip velocity and decreased linearly in double logarithmic plot from about 30 (at 0.5.degree./s) to about 9 at (5.degree./s). For retinal slip velocities larger than 5.degree./s open-loop gain decayed faster and reached about 1 at 30.degree./s. Step response profiles showed a gradual increase in slow phase eye velocity reaching steady-state after a time period roughly proportional to stimulus velocity. Initial low phase velocity measured within 500 ms after stimulus onset reached between 2 and 4.degree./s and was largely independent of stimulus amplitudes above 10.degree./s. Occasionally rats showed fast rises in slow phase eye velocity at the onset of the step response profiles. Primary and secondary optokinetic afternystagmus were present. Duration of primary afternystagmus was largely independent of stimulus amplitude and lasted 8.0 .+-. 4 s. Closed-loop gain of steady-state step responses in monocular vision was, for temporonasal stimuli, similar to that measured in binocular condition while for nasotemporal stimulation gain was much smaller even at low stimulus velocities. Sinusoidal modulation of slow phase velocity was linearly dependent on stimulus velocity; the linear range decreased as frequency of stimulation increased. Slow phase velocity gain was relatively constant (.apprx. 0.8) between 0.05 and 0.3 Hz and showed only a small tendency to decrease at larger stimulus frequencies. Phase-lag increased strongly with stimulus frequency and could be fitted by assuming a response time delay of 100 ms. The rat's optokinetic system is evidently qualitatively similar to that found in the rabbit. At a quantitative level, however, fact and slow optokinetic response dynamics appear to be better developed in the rat than in the rabbit. Although the optokinetic response properties of both species are clearly different from frontal-eyed animals as far as response symmetry in monocular condition is concerned, they nevertheless share with them the basic system properties such is velocity storage and fast response characteristics.
Desc.: RABBIT PHASE EYE VELOCITY LATERAL EYE RESPONSE DYNAMIC
Concept Codes: CYTOLOGY/CYTOCHEM-ANIMAL (*02506); ANATOMY/HISTOL-COMPARATIVE (*11103); SENSE ORGANS-GENL STUDS, MET HS (20001); SENSE ORGANS-PHYSIOL, BIOCHEM (*20004); NERVOUS SYST-GENL STUDS, METHS (*20501); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504)
Biosystematic Codes: LEPORIDAE (86040); MURIDAE (86375)

Y017005 58 
8004320
OSMOTICALLY CONTROLLED-DELIVERY OF METOPROLOL IN MAN IN-VIVO PERFORMANCE OF OROS SYSTEMS WITH DIFFERENT DURATIONS OF DRUG RELEASE
GODBILLON J; GERARDIN A; RICHARD J; LEROY D; MOPPERT J
BIOPHARMACEUTICAL RES. CENT., CIBA-GEIGY BP 308, 92506 RUEIL MALMAISON CEDEX, FRANCE.
BR J CLIN PHARMACOL 19 (SUPPL. 2). 1985. 213S-218S. CODEN: BCP?B
Lang.: Eng.
In vivo absorption from 19/190 and 19/285 metoprolol Oros drug delivery systems was assessed by measuring plasma drug concentrations after single administration of the systems to 6 healthy volunteers. The initial in vitro release rate for both Oros preparations was 19 mg/h but they contained 190 or 285 mg of metoprolol fumarate. The plasma concentration-time profiles for both Oros dosage forms were consistent with an extended duration of release and absorption from the gastrointestinal tract. Analysis of the plasma level data indicated that the rate and duration of in vivo absorption closely mirrored the in vitro release behavior of the 19/190 and 19/285 systems, but the in vivo profiles showed a 1-2 h initial delay. The administration of the 19/190 system on 2 occassions to the same 6 volunteers indicated that in vivo release of drug from this Oros preparation was reproducible.
Desc.: DRUG DELIVERY SYSTEM PHARMACOKINETICS
Concept Codes: CLIN BIOCHEM-GENL STUDIES (10006); BIOCHEM STUD-GENERAL (10060); METABOLISM-GENL STUD, METAB PATHW (13002); DIGESTIVE SYST-PHYSIOL, BIOCHEM (14004); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003) ; PHARMICOL-CLINICAL PHARMACOL (*22005); IN VITRO STUDS-CELLULR, SUBCELL (32600)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 59 
80042947
PHARMACODYNAMICS COMPARISON OF VERAPAMIL AND NIFEDIPINE IN ANESTHETIZED DOGS
HAMANN R; KALTENBORN K E; MCALLISTER R G JR
RES. DEV., VETERANS ADM. MED. CENT., LEXINGTON, KY. 40511, USA.
J CARDIOVASC PHARMACOL 7 (2). 1985. 224-231. CODEN: JCPCD
Lang.: Eng.
The relationships between steady-state plasma concentrations of verapamil or nifedipine and the resultant hemodynamic and electrophysiologic effects were evaluated in anesthetized, instrumented dogs. In different groups of animals, the drugs were given i.v. by loading maintenance infusions designed to rapidly achieve and sustain stable plasma drug concentrations over 4 different target ranges which span those found in clinical use of these agents. Plasma levels of nifedipine varied from 5 to 125 ng/ml, and those of verapamil, from 40 to 500 ng/ml, and those of verapamil, from 40 to 500 ng/ml. Nifedipine produced no apparent effects on the surface ECG. Verapamil dosing resulted in progressive prolongation of the PR interval as plasma drug levels increased from 40 to 250 ng/ml; at higher drug levels, complete atrioventricular block occurred. At the highest plasma concentrations used, the maximal vasodilation produced by both drugs was approximately equal, with mean aortic pressure levels falling to 50-60% of control values. The effects of the 2 agents on cardiac pump performance differed: nifedipine administration produced dose-related increases in cardiac output at all plasma drug concentrations studied; the effects of verapamil were critically dependent upon drug levels in plasma with cardiac output increased above control values at drug concentrations between 40 and 250 ng/ml, and progressively depressed at higher plasma levels of the drug. As a result, the calculated systemic vascular resistance declined progressively during nifedipine administration while after verapamil doses, this parameter varied inversely with observed effects on cardiac output. These in vivo data illustrate the potent and generalized vascular effect of both nifedipine and verapamil, and, in addition, emphasize fundamental differences between these 2 agents, which derive from the direct myocardial depressant effects of verapamil.
Desc.: CARDIOVASCULAR-DRUG SYSTEMIC VASCULAR RESISTANCE CARDIAC PUMP PERFORMANCE ATRIOVENTRICULAR BLOCK HEMODYNAMICS PHARMACOKINETICS
Concept Codes: COMPARATIVE BIOCHEM-GENL STUDIES (10010); BIOCHEM STUD-GENERAL (10060); METABOLISM-GENL STUD, METAB PATH (13002); CARDIOVASC SYST-GENL STUDS, METHS (14501); CARDIOVASC SYST-PHYSIOL, BIOCHEM (*14504); CARDIOVASC SYST-HEART PATHOLOGY (*14506); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (*15002); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-CARDIOVASC SYST (*22010); ROUTES OF IMMUNIZ, INFECT, THERAP (22100)
Biosystematic Codes: CANIDAE (85765)

Y017005 60 
80038752
OPTIMAL HARVESTING WITH EXPONENTIAL GROWTH IN AN ENVIRONMENT WITH RANDOM DISASTERS AND BONANZAS
YAN D; HANSON F B
DEP. MATH. STAT., WRIGHT STATE UNIV.TON, OHIO 45435, USA.
MATH BIOSCI 74 (1). 1985. 47-58. CODEN: MABIA
Lang.: Eng.
The optimal discounted present value of an exploited population under constant effort harvesting in an environment with random disasters and bonanzas is investigated. The deterministic component of growth is density independent (also called Malthusian or exponential). The disasters and bonanzas are random, occurring at the times of events of a Poisson process. The density independent properties of the model and the constant effort open loop policy lead to an exact solution for the expected present value. The optimal expected present value is compared with those in deterministic models with and without deterministic type jumps. Deterministic and random jumps can have a significant influence on the optimal present value. The effort to achieve the optimal is not sensitive to variations in the total jump frequency or in the discount rate. The average random jump model is much easier to apply than the deterministic jump model. Bonanzas can have much more of an effect on the present value than disasters given similar jump rates.
Desc.: EXPLOITED POPULATION DETERMINISTIC JUMP MODEL
Concept Codes: MATHEMATIC BIOL/STATISTIC METH (*04500); ECOLOGY-GENL STUDIES, METHODS (*07502); BIOPHYS-BIOCYBERNETICS (10515)

Y017005 61 
80037779
PLATELET INHIBITORS AND HYDROXYETHYL STARCH SAFE AND COST-EFFECTIVE INTERVENTIONS IN CORONARY ARTERY SURGERY
HICKS G L JR; JENSEN L A; NORSEN L H; QUINN J R; STEWART S S; DEWEESE J A
UNIV. ROCHESTER MED. CENT., 61 ELMWOOD AVE., ROCHESTER, N.Y. 14642.
ANN THORAC SURG 39 (5). 1985. 422-425. CODEN: ATHSA
Lang.: Eng.
Cost-effectiveness and clinical safety of utilizing hetastarch in pump prime solutions and for colloid replacement postoperatively in conjunction with the platelet inhibitors, aspirin and Persantine (dipyridamole) were evaluated. Adult patients (64) undergoing a coronary artery bypass operation were divided into 2 groups. Group 1 (n = 32) received only persantine (75 mg 3 times a day) on the day prior to operation. Group 2 (N= 32) receved the same persantine dose plus aspirin (325 mg). In both groups, aspirin and persantine were continued postoperatively and hetastarch was used as the colloid of choice. All patients were elvuated for blood loss coagulation profiles, cost of blood and colloid replacement, and clinical course. Group 2 patients demonstrated significantly greater blood loss (P < 0.05) but the same postoperative coagulation profiles as group 1. The transfusion requirment (3.6 units vs. 1.3 units) and cost basis for patients care were higher in group 2. Hetastarch had no effect on blood loss and was not associated with any adverse clinical reactions. Annual institutional savings based on utilization of hetastarch were calculated. Preoperative administration of aspirin (325 mg) is associated with increased perioperative blood loss and higher patient costs, 2 variables not demonstrable with persantine only. Use of hetastarch combined with postoperative platelet inhibition was clinically safe and was a cost-effective esponse time [t90%] of 50 s or less. [Precise control of blood glucose concentrations [in human diabetics] necessitates a closed-loop device which delivers insulin to the systemic blood supply in proportion to the difference between the desired and measured physiological glucose concentration. There is therefore a need for in vitro glucose transducers for clinical applications.]
Desc.: HUMAN DIABETES BLOOD GLUCOSE CONCENTRATION INSULIN INFUSION PUMP CELLULOSE ACETATE CURRENT YIELD MECHANICAL STABILITY
Concept Codes: CLIN BIOCHEM-GENL STUDIES (*10006); BIOCHEM METH-PROTNS, PEPTDS, AM AC (10054); BIOCHEM METH-CARBOHYDRATES (*10058); BIOCHEM STUD-PROTEIS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-CARBOHYDR. (10068); BIOPHYS-GENERAL BIOPHYS TECH (*10504); BIOPHYS-BIOENGINEERING (*10511) ; EXTERN EFF-ELECTR, MAGNET, GRAVITY (*10610); ENZYMES-METHODS (*10804); PATHOLOGY-THERAPY (*12512); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-METABOLIC DISORDERS (*13020); CARDIOVASC SYST-GENL STUDS, METHS (14501); BLOOD/BODY FLDS-GENL STUDS, METHS (*15001); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (*15002); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 71 
80018388
ULTUNA MACHINERY DATA-BASE A DESCRIPTION
LEUCHOVIUS T
SVER LANTBRUKSUNIV INST ARBETSMETOD TEK RAPP 0 (96). 1985. 1-24. CODEN: R?ITD
Lang.: SWEDISH
Ultuna Machinery database [Ultuna Mach. d.b.] is a computerized information system developed by the Department of Agricultural Engineering at the Swedish University of Agricultural Sciences. It contains specifications for agricultural machinery and some energy equipment sold in Sweden. It was designed to meet the needs of a well classified survey of marketed equipment. The database is, or will be used, by advisers, farmers, dealers, schools, etc. Ultuna Mach. d.b. contains 25 different groups of common field machinery and a few groups with energy equipment (boilers, heat pumps, etc). There is also a common index of dealers and products/makes. In total > 500, 000 data are stored. Chapter 4 contains a system description. Programs are developed for storing new models as well as for updating and information retrieval. Only the information retrieval programs may be used by external users. The program language is Fortran IV with direct access functions. Chapter 5 describes the programs. Data is stored in 2 different files for each category of machines. The 1st of those stores all information and is used for print-outs from the database. The 2nd one contains only numeric data. It is inverted (each record contains all model's value of a certain property) to allow for short searching time. Ultuna Mach. d.b. is implemented on the computer of Uppsala University Computing Centre (UDAC) and is used today: for information retrieval on-line from data terminals and personal computers; for continuous on-line updating; for calculations and comparisons of stored data; as an aid for publishing data books that contains a subsample of the database; and to produce market surveys for the agricultural press.
Desc.: SWEDEN AGRICULTURAL MACHINERY ENERGY EQUIPMENT
Concept Codes: GENL BIOL-INFRMTN, DOCU, COMP APPL (*00530); AGRONOMY-GENL, MISC, MIXED CROPS (*52502)

Y017005 72 
80016183
CNTROLLED RELEASE OF PILOCARPINE HYDROCHLORIDE FROM ETHYLENE-VINYL ALCOHOL COPOLYMER MATRICES
HOU W-M; MIYZAKI S; TAKADA M
FAC. PHARAMCEUTICAL SCI., HIGASHI-NIPPON-GAKUEN UNIV., ISHIKARI-TOHBETSU, HOKKAIDO 061-02, JPN.
CHEM PHARM BULL (TOKYO) 33 (3). 1985. 1242-1248. CODEN: CPBTA
Lang.: Eng.
An ethylene-vinyl alcohol (EVAl) copolymer was evaluated as a new carrier for a long-acting delivery system of pilocarpine-hydrochloride. The release characteristics of pilocarpine-EVAl copolymer matrix (film or beads) systems were investigated in in vitro and in vivo [rabbit] test models. The results of the in vitro study suggested that the drug release rate could be easily controlled by modifying the proportions of ethylene and vinyl alcohol in the copolymer. Sustained release can be obtained by using EVAl copolymer containing more ethylene. The results of the in vivo study indicated that the use of the pilocarpine-EVAl copolymer bead system is more effective than that of the conventional liquid dosage form for prolonging the duration of a desired pupillary response. Its biocompatibility, flexibility and heat processability suggest that EVAl copolymer to be a good candidate for pilocarpine delivery into the eye.
Desc.: RABBIT OPHTHALMIC-DRUG DRUG DELIVERY
Concept Codes: BIOCHEM METH-GENERAL (10050); BIOCHEM STUD-GENERAL (10060); SENSE ORGANS-PHYSIOL, BIOCHEM (*20004); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-SENSE ORGANS (*22031); IN VITRO STUDS-CELLULR, SUBCELL (32600); PLANT PHYSIOL-CHEM CONSTITUENTS (51522); PHARMACOGNOS?/PHARMACEUT BOTANY (54000)
Biosystematic Codes: LEPORIDAE (86040)

Y017005 73 
80015886
BIOADHESIVE POLYMERS AS PLATFORMS FOR ORAL CONTROLLED DRUG DELIVERY 3. ORAL DELIVERY OF CHLOROTHIAZIDE USING A BIOADHESIVE POLYMER
LONGER M A; CH'NG H S; ROBINSON J R
SCH. PHARMACY, UNIV. WISCONSIN-MADISON, MADISON, WI 53706.
J PHARM SCI 74 (4). 1985. 406-411. CODEN: JPMSA
Lang.: Eng.
Bioadehsive polymers that bind to the gastric mucin or epithelial cell surface are useful in drug delivery for the purposes of retaining a dosage from in the GI [gastrointestinal] tract and increasing the intimacy and duration of contact of drug with the absorbing membrane. Polycarbohil was previously shown to have bioadhesive properties in the rat stomach and small intestine and was employed in the present study with a sustained-release delivery system to demonstrates improved drug delivery. Using chlorothiazide as the model drug, drug containing albumin beads were prepared and used as the sustained-release system. The beads were physically mixed with equally sized particles of polycarbophil and placed in a capsule to produce a bioadhesive dosage form. When the dosage form contacts the stomach, the gelatin capsule dissolves, exposing the polycarbophil to the bathing fluid. The bioadhesive polymer rapidly hydrates, retaining the albumin beads and attaching to the mucin coating of the stomach. Plasma drug levels in rats showed a longer duration of action and greater bioavailabiity for the bioadhesion dosage from than for either albumin beads or drug powder alone. The principle of bioadhesion may significantly improve therapy, due to a reduced rate of gastric emptying, an increase in contact time and the intimacy of contact of the drug with the absorbing membrane.
Desc.: RAT POLYCARBOHIL PHARMACEUTICAL ADJUNCT-DRUG CAPSULE PHARMACOKINETICS
Concept Codes: CYTOLOGY/CYTOCHEM-ANIMAL (02506); BIOCHEM STUD-GENERAL (10060); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-MOLECUL PROP, MACROMOLEC (10506); BIOPHYS-MEMBRANE PHENOMENA (10508); METABOLISM-GENL STUD, METAB PATHW (13002); DIGESTIVE SYST-PHYSIOL, BIOCHEM (*14004); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); DENTAL/ORAL BIOL-GENL STUD, METHS (19001); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003) ; ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: MURIDAE (86375)

Y017005 74 
80015884
BIOADHESIVE POLYMERS AS PLATFORMS FOR ORAL CONTROLLED DRUG DELIVERY 2. SYNTHESIS AND EVALUATION OF SOME SWELLING WATER-INSOLUBLE BIOADHESIVE POLYMERS
CH'NG H S; PARK H; KELLY P; ROBINSON J R
SCH. PHARMACY, UNIV. WISCONSIN, MADISON, WI 53706.
J PHARM SCI 74 (4). 1985. 399-405. CODEN: JPMSA
Lang.: Eng.
A series of cross-linked, swellable polymers was synthesized from monomers such as acrylic acid, methacrylic acid and others with various cross-linking agents to produce a range of polymers differing in charge densities and hydrophobicity. The densities, rate and extent of hydration of the polymers were determined. An increase in the number of hydrophobic groups in the polymer structure reduced hydration whereas the density of the polymer was unaffected. A sensitive in vitro method for measuring adhesion of polymer to tissue from the rabbit stomach was developed. Polymers of acrylic acid loosely cross-linked (0.3%, w/w [weight/weight]) with different agents, divinyl glycol, 2, 5-dimethyl-1, 5-hexadiene and divinylbenzene, showed the same degree of bioadhesion while poly (methacrylic acid-divinylbenzene) showed reduced bioadhesion. The small percent of cross-linking agent, irrespective of physicochemical properties, did not contribute substantially to bioadhesion, whereas the starting monomer had a large effect. The effect of pH on the bioadhesion of poly (acrylic acid-diviny glycol) was studied at constant temperature, ionic strength and osmolality. The polymer showed maximum adhesion at pH 5 and 6 and a minimum at pH 7. Gastrointestinal transit studies of cross-linked polymers in rats were studied. Poly (acrylic acid-divinyl glycol) and poly (methacrylic acid-divinylbenzene) had substantially longer GI [gastrointestinal] transit times than the control, Amberlite 200 resin beads. The delay in transit time was due to bioadhesion of the polymer to the mucin-epithelial cell surface which was clearly observable on animal autopsy. The acrylic acid polymer showed a longer GI transit time than the methacrylic acid polymer, and this in vivo GI transit result is consistent with in vitro bioadhesion test results.
Desc.: RABBIT RAT POLYACRYLIC-ACID-DIVINYLGLYCOL POLYMETHACRYLIC-ACID-DIVINYLBENZENE PHARMACEUTICAL ADJUNCT-DRUG GASTROINTESTINAL TRANSIT TIME PHARMACOKINETICS
Concept Codes: CYTOLOGY/CYTOCHEM-ANIMAL (02506); BIOCHEM STUD-GENERAL (*10060); BIOPHYS-MOLECUL PROP, MACROMOLEC (10506); BIOPHYS-MEMBRANE PHENOMENA (10508); METABOLISM-GENL STUD, METAB PATHW (13002); DIGESTIVE SYST-PHYSIOL, BIOCHEM (*14004); DENTAL/ORAL BIOL-GENL STUD, METHS (19001); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003) ; ROUTES OF IMMUNIZ, INFECT, THERAP (*22100); IN VITRO STUDS-CELLULR, SUBCELL (32600)
Biosystematic Codes: LEPORIDAE (86040); MURIDAE (86375)

Y017005 75 
80015837
A SEMI-CLOSED LOOP COMPUTER-ASSISTED INSULIN INFUSION SYSTEM HOSPITAL USE FOR CONTROL OF DIABETES IN PATIENTS
CHISHOLM D J; KRAEGEN E W; BELL D J; CHIPPS R
GARVAN INSTITUTE OF MEDICAL RESEARCH, ST. VINCENT'S HOSPITAL, DARLINGHURST, NSW 2010.
MED J ASST 141 (12-13). 1984 (RECD. 1985). 784-789. CODEN: MJAUA
Lang.: Eng.
Closed loop insulin delivery systems are impractical for widespread hospital use. Thus, a semiclosed loop computer-assisted insulin infusion system (CAIIS) was developed for the i.v. delivery of insulin. In its basal program, insulin delivery is determined by blood glucose measurements at intervals of 3 h, while the open-loop metal program delivers 7.5 units over 3 h. Control of meal-induced hyperglycemia was satisfactory in 6 subjects with diabetes tested over 2-4 days, as was mean glycemic control in the 4 non-obese subjects (7.1 .+-. 0.8 mmol/l). To allow for variations in insulin sensitivity, an adjustment incrementing or decrementing the basal insulin delivery rate was applied according to the progressive blood glucose response. Empirical use of this adjustment resulted in good control
(mean blood glucose level, 4.1-7.5 mmol/l) in 10 additional subjects with diabetes. This study demonstrates the potential usefulness of a semi-closed loop insulin infusion system.
Desc.: HORMONE-DRUG BLOOD GLUCOSE LEVEL DRUG DELIVERY SYSTEM INTRAVENOUS MEAL INDUCED HYPERGLYCEMIA
Concept Codes: GENL BIOL-INFRMTN, DOCU, COMP APPL (00530); CLIN BIOCHEM-GENL STUDIES (10006); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOCHEM STUD-CARBOHYDR. (10068); BIOPHYS-BIOENGINEERING (*1051?); METABOLISM-CARBOHYDRATES (*13004); METABOLISM-METABOLIC DISORDERS (*13020); NUTRITION-PATHOGENIC DIETS (*13216); NUTRITION-CARBOHYDRATES (*13220); CARDIOVASC SYST-GENL STUDS, METHS (*14501); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); ENDOCRINE SYST-PANCREAS (*17008); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-ENDOCRINE SYST (*22016); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 76 
80015759
EFFECT OF OMEPRAZOLE AND CIMETIDINE ON DUODENAL ULCER A DOUBLE-BLIND COMPARATIVE TRIAL
LAURITSEN K; RUNE S J; BYTZER P; KELBAEK H; JENSEN K G; RASK-MADSEN J; BENDTSEN F; LINDE J; HOJLUND M; ET AL
DEPARTMENT OF MEDICAL GASTROENTEROLOGY, GLOSTRUP HOSPITAL, DK-2600 GLOSTRUP, DENMARK.
N ENGL J MED 312 (15). 1985. 958-961. CODEN: NEJMA
Lang.: Eng.
A double-blind randomized study of 132 patients was conducted to determine whether the new, investigational proton-pump inhiibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer. After 2 wk of treatment, which as completed by all patients, the healing rates were 73% in the omeprazole group and 46% in the cimetidine group (P < 0.01). After 4 wk of treatment, which was completed by 118 patients, the corresponding figures were 92 and 74% (P < 0.05). In the omeprazole group 55% of the patients were free of pain after the 1st wk, as compared with 40% of thpse treated with cimetidine (P > 0.05). No major clinical or biochemical side effectds of omeprazole or cimetidane were noted. A 6 mo. follow-up study revealed no significantly difference between the recurrence rates after omeprazole and after cimetidine. In May 1984 clinical trials with omeprazole were temporarily suspended, since a study of long-term toxicity in rats had shown the development of gastric carcinoid tumors.
Desc.: HUMAN ANTIULCER-DRUG HEALING PAIN RELIEF TOXICITY CARCINOGENESIS
Concept Codes: BIOCHEM STUD-GENERAL (10060); ANATOMY/HISTOL-REGEN, TRANSPLANT (*11107); PATHOLOGY-INFLAMMATN, INFLAM DIS (12508); PATHOLOGY-THERAPY (12512); DIGESTIVE SYST-GENL STUDS, METHS (14001); DIGESTIVE SYST-PATHOLOGY (*14006); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-DIGESTIVE SYST (*22014); TOXICOL-PHARMACOLOGICAL (22504); NEOPLSMS/NEOPL AGNTS-CARCINOGENS (24007)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 77 
80014984
NEW DOUBLE-LUMEN POLYETHYLENE CANNULA FOR PUSH-PULL PERFUSION OF BRAIN TISSUE IN-VIVO
MYERS R D; REZVANI A H; GURLEY-ORKIN L A
DEP. OF PSYCHIATRY, UNIV. OF NORTH CAROLINA SCHOOL OF MEDICINE, CHAPEL HILL, NC 27514, USA.
J NEUROSCI METHODS 12 (3). 1985. 205-218. CODEN: JNMED
Lang.: Eng.
A new concept in the design of a push-pull cannula device for localized perfusion of brain tissue in the conscious and/or unrestrained animal is described. A catheter, consisting of a single strand of polyethylene tubing, contains an internal dividing septum which runs longitudinally throughout its length. The orifice of each lumen is of equal diameter and provides an integrated system for simultaneous delivery and withdrawal of a perfusate from the perfusion locus. The prinicipal features of the new cannula system are: its simplicity of fabrication due to its all-plastic construction; multiple tip configurations adapted for a specific anatomical requirement including V-shaped, slanted, horizontal and side-by-side opening; direct visualization of the prefusate monitor bubble through the wall of the transparent catheter; since there are no joints, lack of leakage of perfusate and occlusion of pull channel; ease of sterilization by liquid or gas methods; and infrequency of damage because of catheter flexibility. Using radiolabeled dopamine and norepinephrine, prototype experiments crried out with 3 flow rates and 3 tip configurations revealed differences in substrate exchange which depend upon a given experimental parameter. The practical advantages are discussed of the new perfusion system in comparison with dialysis needles as well as with more commonly used concentric, metallic push-pull cannulae. Technical applications are presented of the methods for the rat and other animals in which either the pharmacological delivery of a drug over a specified interval or recovery of a neurotransmitter released into the cerebral parenchyma is a principal experimental objective.
Desc.: RAT DOPAMINE NOREPINEPHRINE NEUROTRANSMITTER RECOVERY DRUG DELIVERY SYSTEM RADIOLABEL
Concept Codes: RADIATION BIOL-RADTN, ISOTOP TECH (06504); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); BIOPHYS-GENERAL BIOPHYS TECH (10504); METABOLISM-PROTNS, PEPTDS, AM ACDS (*13012); ENDOCRINE SYST-ADRENALS (*17004); ENDOCRINE SYST-NEUROENDOCRINOLOG (*17020); NERVOUS SYST-GENL STUDS, METHS (*20501); NERVOUS SYST-PHYSIOL, BIOCHEM (*20504); PHARMACOL-NEUROPHARMACOLOGY (*22024); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: MURIDAE (86375)

Y017005 78 
80010463
COLD ISCHEMIC ARREST COMPARISON OF CALCIUM-FREE AND CALCIUM-CONTAINING SOLUTIONS
HENDRIKS F F A; JONAS J; VAN DER LAARSE A; HUYSMANS H A; VAN RIJK-ZWIKKER G H; SCHIPPERHEYN J J
DEPARTMENT OF CARDIOLOGY, ACADEMIC HOSPITAL, RIJNSBURGERWEG 10, 2333 AA LEIDEN, NETHERLANDS.
ANN THORAC SURG 39 (4). 1985. 312-317. CODEN: ATHSA
Lang.: Eng.
Isolated pumping rat hearts perfused with reconstituted blood, were studied to compare the effects of 30 min of ischemic arrest following Ca-free or normal, Ca-containing cold cardioplegia on recovery of mechanical function, lactate production, myocardial ATP concentration and release of creatine kinase (CK). As in clinical situations, the volume of the infusate was only 3-4 times the intracavitary blood volume. Hearts arrested with Ca-free solution showed incomplete recovery of mechanical function; hearts arrested with Ca-containing solution recovered completely. After Ca-free arrest, stroke volume recovered to 76 .+-. 29% of its prearrest value. CK release was significantly higher after Ca-free cardioplagia (7.7 .+-. 4.6 units) than after cardioplegia with normal Ca (2.1 .+-. 1.6 units). Since the addition of only 0.02 mmol Ca ions to a liter of Ca-free solution completely prevented its negative effect. Ca-free cardioplegia may cause limited but pronounced damage to myocardial cells, presumably because it removes Ca from the cellular membranes.sbd.the so-called Ca paradox. Probably due to residual Ca in blood and extracellular fluid, the damage is not so extensive after Ca-free cardioplegia as to be noticeable in clinical surgical situations. Residual Ca in the heart does not exclude the possibility that a Ca paradox occurs in small scattered areas of the heart.
Desc.: RAT CARDIOVASCULAR-DRUG LACTATE PRODUCTION ATP CREATINE KINASE CARDIOPLEGIA
Concept Codes: CYTOLOGY/CYTOCHEM-ANIMAL (*02506); BIOCHEM STUD-NUCL ACD, PURNS, PYRM (10062); BIOCHEM STUD-PROTEINS, PEPTIDES, AMINO ACD (10064); MINERALS (10069); ENZYMES-PHYSIOLOGICAL STUDIES (*10808); ANATOMY/HISTOL-EXPERIMENTAL (*11104); ANATOMY/HISTOL-SURGERY (11105); PATHOLOGY-THERAPY (*12512) ; MINERALS (*13010); METABOLISM-PROTNS, PEPTDS, AM ACDS (*13012); METABOLISM-NUCL ACD, PURINS, PYRIM (*13014); CARDIOVASC SYST-GENL STUDS, METHS (*14501); CARDIOVASC SYST-PHYSIOL, BIOCHEM (*14504); CARDIOVASC SYST-HEART PATHOLOGY (*14506); CARDIOVASC SYST-BLD VESS PATHOL (*14508); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); BLOOD/BODY FLDS-OTHER BODY FLDS (*15010); PHARMACOL-CARDIOVASC SYST (*22020)
Biosystematic Codes: MURIDAE (86375)

Y017005 79 
80006866
BIOAVAILABILITY ASSESSMENT OF A NEW LIQUID CONTROLLED-RELEASE PSEUDOEPHEDRINE PRODUCT
GRAVES D A; ROTENBERG K S; WOODWORTH J R; AMSEL L P; HINSVAR O N
MED. RES. DIV., PENNWALT PHARMACEUTICAL DIV., P.O. BOX 1710, ROCHESTER, N.Y. 14623.
CLIN PHARM 4 (2). 1985 199-203. CODEN: CPHAD
Lang.: Eng.
Development of a liquid controlled-release pseudoephedrine [bronchodilator drug] product is described. Two bioequivalence studies were conducted. In a single-dose study involving 20 subjects, the bioavailabilities of 5 controlled-release suspensions with a broad range of drug-release rates were compared with an immediate-release form of pseudoephedrine HCl in a 4-way crossover, incomplete block, sequence-randomized study. Serial blood sampling up to 36 h after drug ingestion provided area-under-the-curve (AUC), maximum plasma concentration (Cmax) and time to peak (tmax). In the multiple-dose study, involving 18 subjects, the bioavailability of the optimal formulation determined from the single-dose study was compared with a reference pseudoephedrine HCl syrup. Serial blood sampling up to 12 h after drug ingestion was performed to determine AUC, Cmax and tmax. The single-dose investigation showed that all formulations were bioequivalent except the product with the slowest release rate, which had lower AUC and Cmax values. The results of the multiple-dose study confirmed these findings with the reference syrup. The use of a series of drug formulations with a wide range of release rates permitted selection of an optimal product in addition to providing the nformation needed to ensure continuous production of bioequivalent products.
Desc.: HUMAN BRONCHODILATOR-DRUG SYRUP DRUG RELEASE RATE OPTIMAL FORMULATION DRUG DELIVERY SYSTEM PHARMACOKINETICS
Concept Codes: CLIN BIOCHEM-GENL STUDIES (10006); BIOCHEM STUD-GENERAL (10060); BIOPHYS-GENERAL BIOPHYS TECH (10504); PATHOLOGY-THERAPY (12512); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); RESPIRATORY SYST-PATHOLOGY (*16006); PHARMACOL-DRUG METAB, METAB STIMU (*22003); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-RESPIRATORY SYST (*22030)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 80 
80006413
INTERMITTENT DOBUTAMINE HYDROCHLORIDE INFUSIONS IN OUTPATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE
ROFFMAN D S; APPLEFELD M M; GROVE W R; TALESNICK B S; SUTTON F J; NEWMAN K A; REED W P
SCH. PHARMACY, UMD, BALTIMORE, MD. 21201.
CLIN PHARM 4 (2). 1985. 195-199. CODEN: CPHAD
Lang.: ENG.
Patients with severe chronic congestive heart failure were treated with intermittent dobutamine HCl infusions administered on an outpatient basis with a portable infusion device. Patients (11, 8 women and 3 men), age 28-71 yr were given initial dobutamine HCl infusions at a rate of 1-2 .mu.g/kg per min and the dose was gradually increased to a maximum dose of 15 .mu.g/kg per min. Patients were considered dobutamine responders if their cardiac output increased by at least 30% and pulmonary-capillary wedge pressure did not rise. After a sustained hemodynamic response was demonstrated, the infusion was discontinued to assess the patients' symptoms during drug-free intervals. The patients were instructed and trained in proper catheter care after a venous-access catheter was surgically implanted. Patients were also shown how to use the ambulatory infusion pump. The patients were treated with long-term intermittent dobutamine HCl infusions for 3-24 mo. All patients adjusted easily to the routine of catheter and pump care and drug administration. The mean dose of dobutamine HCl resulting in the maximum improvement in cardiac index was 9.4 .mu.g/kg per min. All patients observed an improvement in their symptoms of congestive heart failure during the drug infusions and the intervals between the infusions. There was a mean reduction of 1.2 in New York Heart Association functional class. There were 18 congestive heart failure-related hospital readmissions among the 11 patients during 108 cumulative mo. of long-term dobutamine therapy. The intermittent administration of dobutamine HCl via a portable infusion system appears to have improved the functional capacity of the 11 patients studied. This may be a viable treatment alternative for selected ambulatory patients with severe heart failure who demonstrate hemodynamic improvement with dobutamine.
Desc.: HUMAN CARDIOVASCULAR-DRUG PORTABLE INFUSION DEVISE CARDIAC OUTPUT PULMONARY CAPILLARY WEDGE PRESSURE LONG-TERM TREATMENT DRUG DELIVERY SYSTEM PHARMACOKINETICS
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOPHYS-GENERAL BIOPHYS TEC (10504); BIOPHYS-BIOENGINEERING (*10511); ANATOMY/HISTOL-SURGERY (11105) PATHOLOGY-THERAPY (12512); CARDIOVASC SYST-GEN STUDS, METHS (*14501); CARDIOVASC SYST-HEART PATHOLOGY (*14506); BLOOD/BODY FLDS-BLOOD, LYMPH STUD (15002); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-CARDIOVASC SYST (*22010)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 81 
79107922
CONTROLLED DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY A REVIEW
UENO N; REFOJO M F
EYE RES. INST. RETINA FOUND., 20 STANIFORD ST., BOSTON, MASS. 02114, USA.
FOLIA OPHTHALMOL JPN 35 (10). 1984 (RECD. 1985). 2267-2274. CODEN: NGKYA
Lang.: JAPANESE
Ocular drug delivery systems were developed to improve the therapeutic index and/or to avoid unacceptable adverse effects. Several kinds of drug delivery devices, including soft contact lenses, soluble ocular inserts, scleral buckling materials, a silicone rubber device, Ocusert and osmotic minipump are reviewed.
Desc.: HUMAN CONTACT LENSES OCULAR INSERTS SCLERAL BUCKLING SILICONE RUBBER OCUSERT MINIPUMP
Concept Codes: BIOPHYS-GENERAL BIOPHYS TECH (10504); BIOPHYS-BIOENGINEERING (10511); PATHOLOGY-THERAPY (12512); SENSE ORGANS-GENL STUDS, METHS (20001); SENSE ORGANS-PATHOLOGY (*20006); PHARMACOL-CLINICAL PHARMACOL (*22005); PHARMACOL-SENSE ORGANS (*22031); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100)
Biosystematic Codes: HOMINIDAE (86215)

Y017005 82 
7910?628
THE USE OF A VOLUMETRIC INFUSION PUMP FOR THE INTRAARTERIAL INFUSION OF DRUGS
COOPER A M; LILLIMAN M
DEP ANAESTHESIA AND INTENSIVE THERAPY, PETERBOROUGH DISTRICT HOSPITAL, THORPE ROAD, PETERBOROUGH, CAMBRIDGESHIRE.
ANN R COLL SURG ENGL 67 (1). 1985. 11-12. CODEN: ARCSA
Lang.: Eng.
Volumetric infusion pumps are widely used for i.v. infusions. Their use was extended to the intraarterial infusion of drugs [in humans]. An in vitro evaluation of the performance of such devices, under experimental conditions comparable to an intraarterial infusion was carried out. Results confirmed the accuracy of volumetric infusion pumps for intraarterial infusions. The system was found to be safe, reliable and simple in clinical practice.
Desc.: HUMAN
Concept Codes: BIOCHEM STUD-GENERAL (10060); BIOPHYS-BIOENGINEERING (*10511); CARDIOVASC SYST-GENL STUDS, METHS (*14501); PHARMACOL-GENERAL STUDIES (*22002); PHARMACOL-DRUG METAB, METAB STIMU (*22003); ROUTES OF IMMUNIZ, INFECT, THERAP (*22100); TOXICOL-PHARMACOLOGICAL (22504)
Biosystt Analysis; *COSTS; *Hospital Administration; *Information Systems--Organization and Administration (OG) *Management Information Systems--Organization and Administration (OG);  United States